

Cumulative Index 1989

Volume 73

January	OBESITY, pages 1-269
March	CARDIOVASCULAR PHARMACOTHERAPY III, pages 271-516
May	MEDICAL PROBLEMS IN PREGNANCY, pages 517-752
July	HEPATIC DISEASES, pages 753-1053
September	COLLAGEN VASCULAR DISEASES, pages 1055-1305
November	GERIATRIC MEDICINE, pages 1307-1598

Note: Page numbers of article and issue titles are in **boldface** type.

Abdomen, acute, in elderly, 1413-1422. See also *Acute abdomen*.
Abdominal fat, genetics and, 73-75
Abdominal-gluteal ratio, 163
for body fat determination, 7
Abdominal pain, in familial type V hyperlipoproteinemia, 873
Abortion, definition of, 517
in AIDS patient, 706
induced, and coagulopathy, 736-737
Abruptio placentae, and disseminated intravascular coagulation, 730-732
Accelerated aging theory, of Alzheimer's disease, 1386
Accutane, teratogenic effects of, 576
Acetaminophen, metabolism of, and liver disease, 786
Acetazolamide, and metabolic acidosis generation, 279
Acetic acid, cutaneous reactions to, 1278-1279
Acid-base abnormalities, in fulminant hepatic failure, 961
Acne, with corticosteroids, 1284
Acrodermatitis chronica atrophica, localized scleroderma vs, 1152-1153
Actin, in cardiac muscle tension, 286
Action tremor, in elderly, 1308
Activity, in management of juvenile dermatomyositis, 1204
Acute abdomen, in elderly, 1413-1422
causes of, 1417
differential diagnosis of, 1416-1420
emergency operations for, 1418
initial evaluation of, 1413-1416
mortality in, 1418
outcome of, 1420-1421
sepsis in, inaccurate diagnosis of, 1419
Acute confusional state, clinical description of, 1399
Acyclovir, for chronic hepatitis B, 976
Adaptive devices, role in falls, 1328
Adipocytes, composition of, 84-89
differentiation of, 91
lipid mobilization from, 84
nutritional regulation of, 90
precursors of, 91
triglyceride uptake by, 84
Adipose tissue, anatomic characteristics of, 161-162
androgenic activity and, 128-129
cellularity of, 89-93
fatty acid composition of, 84
growth potential of, 128
metabolism of, 87
Adiposity, obesity vs, 117
regional, metabolic risk factors in, 127-131
Adrenal function, in obesity, 146-147, 170

Adrenal steroids, and nutrient balance control, 39
fetal exposure to, 677

Adrenergic agents, for asthma in pregnancy, 658

Adrenergic blockers, effect on serum lipids, 465

Afferent signals, of nutrient balance, 34-36

Aflatoxins, and hepatocellular carcinoma, 1005

Afterload, in muscle contraction, 286

Aging. See also *Elderly*.
and lipoprotein metabolism, 1525-1526
and sexual function, 1483-1495
bone loss with, 1455
factors in, 1531
male hormonal changes with, 1484-1485
nutrition and, 1531-1549

Agitation, in dementia, treatment of, 1404

Agnosia, in primary degenerative dementia of the Alzheimer's type, 1396

Agraphesthesia, with cerebral infarction, 1362

AIDS, and abortion, 706
breastfeeding in, 593
dementia in, 1398
fetal syndrome of, 704
in women, transmission and distribution of, 702
risk factors for, 701

Air-fluidized beds, for pressure ulcer treatment, 1518

Air mattresses, for pressure ulcer treatment, 1517

Albumin, in liver failure, 943
laboratory standards for, 1541
measurement of, in elderly, 1539

Alcohol use, amnestic disorder with, 1399
and drug metabolism, 786
and impotence, 1487
role in falls, 1329
teratogenic effects of, 570-571

Alcoholic liver disease, 815-830. See also under *Liver disease*.

Alkalosis, in hepatic encephalopathy, 796

Alopecia, in discoid lupus erythematosus, 1056, 1058
in systemic lupus erythematosus, 1104

Alpha-adrenergic agents, for stress incontinence, 1435

Alpha-adrenergic blockers, for Raynaud's phenomenon, 1137

Alpha-antitrypsin deficiency, and hepatocellular carcinoma, 1002-1003
liver transplantation for, 1017

Alpha-blockers, effect on plasma lipids, 462
effect on serum lipids, 464

Alpha-fetoprotein, in hepatocellular carcinoma, 992-993
maternal, in diabetes, 691-692
in fetal diagnosis, 530

Alstrom-Hallgren syndrome, and obesity, 166

Alzheimer's disease, and urinary incontinence, 1424
diagnosis of, criteria for, 1397
theories of, 1384-1386

Amebiasis, and liver abscess, 853

Amino acids, branched-chain, for hepatic encephalopathy, 805-806
for alcoholic liver disease, 825

Aminophylline, for acute asthma in pregnancy, 656

Aminopterin, teratogenic effects of, 573-574

Ammonia, in hepatic encephalopathy, 800-801

Amnestic syndromes, clinical description of, 1399-1400
diagnostic criteria for, 1395

Amniocentesis, in fetal diagnosis, 531-532
in maternal diabetes, 693

Amniotic fluid embolus, and disseminated intravascular coagulation, 735-736

Ampicillin, for urinary tract infections, 1445

Amrinone, chemical structure of, 304
for congestive heart failure, 303-304
hemodynamic response to, 305

Analgesics, and liver disease, 778, 787

Androgens, and hepatocellular carcinoma, 1004

Anemia, and secondary hemochromatosis, 838
in acute abdomen, 1415
in protein-calorie malnutrition, 1543
in pyogenic liver abscess, 849

Anencephaly, with maternal diabetes, 691

Anesthetics, and liver disease, 778, 787

Angina pectoris, myocardial infarction prevention in, 410-411

Angioplasty, recombinant tissue-type plasminogen activator therapy vs, 398

Angiotensin, maternal vascular sensitivity to, 543

Angiotensin-converting enzyme(s), effect on serum lipids, 466

Angiotensin-converting enzyme inhibitors, adverse effects of, 330-332
clinical efficacy of, 326-328
effect on electrolytes, 323-325
effect on mortality, 329-330
for hypertension, in elderly, 1477
in pregnancy, 634, 672-674
for hyponatremia, 280
hemodynamic effects of, 320-322
humoral effect of, 320
in heart failure, 315-338
renal effects of, 323-325
spectrum of response to, 322

Animals, obesity in, 23

Ankylosis, digital, in systemic scleroderma, 1170

Anomia, in primary degenerative dementia of the Alzheimer's type, 1396

Anorexia, in pyogenic liver abscess, 849

Anorexiant drugs, effectiveness of, 241-242 for obesity, 237-240

Anthranilic acids, cutaneous reactions to, 1281-1282

Anthropometrics, of elderly, in nutritional assessment, 1537-1539

Antiarrhythmic drugs, and liver disease, 787

Antibiotics, contraindicated in newborns, 592 for acute asthma in pregnancy, 657 for hepatic encephalopathy, 806 for pressure ulcer treatment, 1519-1520

Anticardiolipin antibody, in systemic lupus erythematosus, effect on pregnancy, 611 screening for, 615

Anticholinergics, for urge incontinence, 1435

Anticoagulants, circulating, and coagulopathy, 738 for cardiogenic embolism, 1365 in pregnancy, 647-648 teratogenic effects of, 571-572

Anticonvulsants, and liver disease, 778, 787 half-lives of, 598 in pregnancy, 662-664 teratogenic effects of, 572-573

Antidepressants, in orthostatic hypotension, 1345 role in falls, 1330

Antifibrotic agents, for alcoholic liver disease, 825

Antigout agents, and liver disease, 778

Antihistamines, for cutaneous drug reactions, 1294 for leukocytoclastic vasculitis, 1232

Antihypertensive therapy, drugs for, and impotence, 1487 in breast milk, 600 in elderly, benefits of, 1474

Anti-inflammatory drugs, and liver disease, 778, 787-788 for systemic scleroderma, 1175

Antilymphocyte globulin, for immunosuppression, in liver transplantation, 1026

Antimalarials, cutaneous reactions to, 1284-1285 fetal effects of, 613 for cutaneous lupus erythematosus, 1068, 1085 for lupus erythematosus panniculitis, 1124

Antimicrobials, and liver disease, 778, 787

Antineoplastics, and liver disease, 779, 788 teratogenic effects of, 573-574

Antinuclear antibodies, in localized scleroderma, 1149 in lupus erythematosus panniculitis, 1123 in systemic scleroderma, 1173, 1174

AntiParkinsonism drugs, in orthostatic hypotension, 1345

Antipressure devices, for pressure ulcer treatment, 1517-1519

Antipsychotic drugs, in orthostatic hypotension, 1344-1345

Antispasmodics, and liver disease, 778 for constipation, 1504-1505 for urge incontinence, 1435

Antithrombin, function of, in coagulation, 725

Antithymocyte globulin, for immunosuppression, in liver transplantation, 1026-1027

Antithyroid drugs, teratogenic effects of, 574-575

Anti-ulcer drugs, and liver disease, 788

Anxiety, in obesity, 49 in pregnancy, case history of, 552-553

Aortic aneurysm, ruptured, in elderly, emergency operation for, 1418

Aortic insufficiency, in pregnancy, 642

Aortic stenosis, in pregnancy, 642

Aphasia, in cerebral infarction, 1362 in primary degenerative dementia of the Alzheimer's type, 1396

Aphthous ulcers, in Behcet's disease, 1240

ApoC-II, deficiency of, familial, 866-869

Apolipoproteins, 862

Apoproteins, 859-860 electrophoresis of, 875

Appendicitis, in elderly, acute abdomen with, 1416-1418 in pregnancy, case history of, 553

Appetite suppressants, 239-241

Apraxia, in cerebral infarction, 1362 in primary degenerative dementia of the Alzheimer's type, 1396

Aprotinin, for disseminated intravascular coagulation, with abruptio placentae, 732

Arrhythmias, beta-blockers for, 413-415 cardiac, in pregnancy, 646-647 role in falls, 1330 effect of cocaine on, 479 in fulminant hepatic failure, 960 in hemochromatosis, 837

Arterial alterations, in pregnancy, surgical implications of, 550

Arterial blood gases, in acute asthma, 655

Arterial compliance, and orthostatic hypotension, 1341

Arthralgias, with cutaneous vasculitis, 1225 with dermatomyositis, 1186 with scleroderma, 1147, 1172

Arthritis, acute, in elderly, 1375-1376 rheumatoid. See *Rheumatoid arthritis*. with Behcet's disease, 1241 with cutaneous vasculitis, 1225 with dermatomyositis, 1186 with pyoderma gangrenosum, 1253-1254

Arthropathies, crystal-induced, in elderly, 1372-1373
 in hemochromatosis, 837

Arthus reaction, in vasculitis, 1223

Ascites, in hepatic encephalopathy, 796
 in liver failure, 943

Ascorbic acid, deficiency of, and pressure ulcers, 1513
 for hemochromatosis, 840

Asphyxia, fetal sensitivity to, 525
 neonatal, 526

Aspirin, cutaneous reactions to, 1277-1278
 for stroke prophylaxis, 1363

Asthma, in pregnancy, 653-660
 acute, clinical findings in, 654-655
 treatment of, 656-658
 continuing treatment of, 658-659
 factors provoking, 653

Ataxia, with cerebellar tremor, 1315

Atenolol, effect on serum lipids, 458
 for hypertension in pregnancy, 672-674
 in breast milk, 600

Atherosomatous disease, and stroke, 1353

Atherosclerosis, accelerated, in familial hypercholesterolemia, 869
 prevention of, 879-882

ATP, in muscle contraction, 288-289

Atrial fibrillation, and stroke, 1354

Atrial natriuretic factor, diuresis with, 281

Atrial septal defect, in pregnancy, 644

Atrophic vaginitis, and urinary incontinence, 1427

Attention, testing of, in acquired cognitive disorder, 1390

Attitude techniques, in weight control program, 193

Auranofin, cutaneous reactions to, 1286

Autoantibodies, production of, in chronic cutaneous lupus erythematosus, 1067

Autoimmune disorders, and Behcet's disease, 1240
 in pregnancy, 605-621
 poor outcome in, markers for, 609-611
 with primary biliary cirrhosis, 913, 915-916

Autonomic nervous system, and nutrient balance control, 38
 in orthostatic hypotension, 1341, 1343

Aversion, in weight control, 253

Azathioprine, and risk of malignancy, 675
 cutaneous reactions to, 1291-1292
 fetal exposure to, effects of, 612, 677-678
 for immunosuppression, in liver transplantation, 1026
 for primary biliary cirrhosis, 921

Azidothymidine, and liver disease, 788

Azygos blood flow, measurement of, 937-939

Bacteremia, with urinary tract catheterization, 1448

Bacterial endocarditis, prophylaxis for, at delivery, 648

Bacteriuria, with urinary tract catheterization, 1443-1445

Balance, in elderly, effect on falling, 1325, 1332

Balloon tamponade, for esophageal varices, 944

Bardet-Biedl syndrome, and obesity, 166

Basal energy expenditure, in elderly, 1541-1542

Baseline characteristics, in drug trials, failure to control for, 503-504

Bed elevation, for orthostatic hypotension, 1345
 for pressure ulcer prevention, 1516

Bedrest, avoidance of, for orthostatic hypotension, 1345

Behavioral programs, for obesity, 60, 185-201
 cognitive change in, 194
 components of, 190
 conceptual model of, 189
 developmental history of, 185-186
 exercise in, 193
 low calorie diet with, 196
 nutrition in, 193
 pharmacotherapy with, 197
 reinforcement in, 193
 results of, 186-189
 self-monitoring in, 190
 social support in, 193
 stimulus control in, 190
 surgery with, 197

Behavioral therapy, for urge incontinence, 1435

Behcet's disease, diagnosis of, 1239-1242

Benzocaine, for weight control, 245

Benzodiazepines, receptors for, in hepatic encephalopathy, 802-804
 role in falls, 1330

Beta-adrenergic blockers. *See Beta-blockers.*

Beta-adrenergic receptors, catecholamine-induced down-regulation of, beta-blockers for, 376

Beta-agonists, for acute asthma in pregnancy, 656
 for Raynaud's phenomenon, 1137
 for weight control, 245

Beta-blockers, benefit of, mechanisms of, 413-416
 clinical trials of, 411-414, 416-418
 clinical use of, 418-421
 contraindications to, 418
 effect on serum lipids, 460
 for heart failure, 373-385

clinical experience with, 377-380
evidence against, 379-380
rationale for avoiding, 373-374
rationale for using, 374-376
recommendations for, 381-383
for hypertension, in elderly, 1476-1477
in pregnancy, 672-674
for myocardial infarction, 409-436
early phase, 416
recommendations for, 431
in breast milk, 600-601
infarct reduction with, randomized trials of, 417
long-term trials of, results of, 413-414
pharmacologic properties of, 412
plasma lipid changes with, 453-461
with intrinsic sympathomimetic activity, effect on serum lipids, 459

Beta-endorphin, in obesity, 148

Bile, constituents of, metabolic relationships among, 755

Bile acid(s), elevated concentrations of, in primary biliary cirrhosis, 913

Bile acid binding resins, for hyperlipidemia, 1528
lovastatin with, 443

Bile duct(s), cholangiograms of, 902
dilated, imaging of, 901
endoscopic sphincterotomy of, 903

Bile salt, synthesis of, 756

Biliary cirrhosis, primary, 911-929
and hepatocellular carcinoma, 1001-1002
clinical features of, 911-912
course of, 918-919
demographic characteristics of, 911
diagnosis of, 917-918
diseases associated with, 912-913
epidemiology of, 911
liver pathology in, 914
liver transplantation for, 1013-1014
manifestations of, 911-914
pathogenesis of, 915-917
prognosis in, 919
serologic findings in, 913
treatment of, 919-922

Biliary tract, diseases of, imaging of, 899-901
in elderly, acute abdomen with, 1416-1418
drainage of, for gallstones, 761
obstruction of, and pyogenic liver abscess, 848
stents in, 903-905

Biliointestinal bypass, for weight control, 255

Biliopancreatic diversion, for weight control, 256

Bilirubin, in liver failure, 943

Binswanger's disease, dementia in, 1398

Bioelectrical impedance, for body fat determination, 7

Biophysical profile, of fetal status, 537-538

Bipyridines, effects of, 305

Birth weight, and perinatal outcome, 524

Bisacodyl, cathartic dosage of, 1504

Bladder. See also under *Urinary*.
cancer of, with chronic urinary tract catheterization, 1448-1449
disorders of, long-term catheterization for, 1441-1442
dynamics of, in urinary incontinence, 1425
function of, changes with aging, 1426
perforation of, with urinary tract catheterization, 1449

Blood, hypercoagulability of, in pregnancy, 724

Blood flow, evaluation of, in Raynaud's phenomenon, 1134
in pregnancy, 640

Blood pressure, and cardiovascular disease risk factors, 218
changes in, role in falling, 1327
with standing, 1337-1339
effect of cocaine on, 479
orthostatic changes in, 1339-1340

Blood transfusions, and secondary hemochromatosis, 838-839

Blood viscosity, in Raynaud's phenomenon, 1129
inhibitors of, for Raynaud's phenomenon, 1138-1139

Blood volume, increased, in pregnancy, 543

Body composition, effect of caloric restriction on, 231-233
effect of exercise on, 227-233

Body fat, determination of, 1-7
distribution of, 1-7
and endocrine disorders, 130-131
and health risks, 119-131
factors influencing, 127-131
in obesity, 118-120
relationship to metabolic profile, 121
genetics and, 71-73

Body mass-energy expenditure relationship, clinical applications of, 24-25

Body mass index, 4
and risk of obesity, 180
for measurement of overweight, 175
genetic effect on, 72
nomogram for, 176

Body weight, defense of, 206, 238
effect of chronic exercise on, 227-233
lean vs obese, 220-222
physiological regulation of, and obesity, 15-27
set-point of, energy expenditure and, 19

Bone, loss of, effect of calcium on, 1461
mineral density of, and fracture risk, 1458

Bone disease, metabolic, in primary biliary cirrhosis, 919-920

Bone marrow transplant patient, pregnancy in, 681

Bowel bypass syndrome, with Sweet's syndrome, 1238

Bowel resection, for pyoderma gangrenosum, 1257

Bowel retraining, in constipation treatment, 1503

Brain scan, in acquired cognitive disorder, 1393

Breast(s), development of, 584-585
plugged duct in, differential diagnosis of, 596

Breast cancer, in obesity, 114
with primary biliary cirrhosis, 912

Breastfeeding, and medical disease, 583-603
by AIDS patient, 593, 707
by renal transplant patients, 681
drugs in, 588-589
in chicken pox, 594
in diabetes mellitus, 594-597, 695
in epilepsy, 598-599
in heart disease, 599-601
in hepatitis, 593
in herpes simplex, 593-594
in hypertension, 599-601
in infectious disease, 591-594
in mastitis, 592
in noninfectious diseases, 594-601
in thyroid disease, 594-597
in toxic shock syndrome, 592
in tuberculosis, 592
reasons for, 583-584

Breast milk, human immunodeficiency virus in, 705

Breast pumping, of contaminated milk, 590

Brown fat, function of, 99

Bruising, in hepatic encephalopathy, 796

Budd-Chiari syndrome, drug-induced, 782
liver transplantation for, 1018-1019

Bulk agents, cathartic dosage of, 1504

Butterfly rash, in acute cutaneous lupus erythematosus, 1094-1095

Calcification, in lupus erythematosus pan-niculitis, 1119, 1121

Calcinosis, digital, in systemic scleroderma, 1169
in dermatomyositis, 1212
in juvenile dermatomyositis, 1196, 1198
management of, 1205-1206

Calcitonin, for osteoporosis, 1467

Calcium, and muscle contraction regulation, 288-290

binding of, anticoagulant interference with, 571
for osteoporosis, 1460-1462

Calcium antagonists, and heart failure, 339-359
comparison of, 351
effects on cardiac performance, 340
for heart failure, recommendations for, 353
mechanisms of action of, 339-343

Calcium channel blockers, effect on serum lipids, 466
for hypertension, in elderly, 1477
in pregnancy, 633-634, 672-674

in myocardial infarction, 409-436
acute, benefits of, 421
mortality with, 430
recommendations for, 431

Calcium ion channel, slow, inotropic action on, 295-296

Calculation, ability in, with cerebral infarction, 1362

Caloric intake, in elderly, 1534

Caloric restriction, effect on body composition, 231-233
response to, 102

Cambridge diet, for obesity, 210

Cancer, gastrointestinal, in elderly, emergency operations for, 1418
in obesity, 114
inconsistent findings in, 116

Captopril, adverse effects of, 330
clinical efficacy of, 326, 328
effects on serum potassium, 325
effects on serum sodium, 323
for chronic congestive heart failure, hemodynamic effects of, 320
in breast milk, 601
nifedipine vs, 348
placebo vs, mean diastolic blood pressures in, 502
renal effects of, 324
side effects of, 330

Carbamazepine, in breast milk, 599
in pregnancy, 664

Carbohydrates, dietary, for elderly, 1536
intolerance to, in hemochromatosis, 836
role in obesity, 103-104

Carbonic anhydrase inhibition, effects of, 272

Carcinoma, evaluation for, with constipation, 1500
hepatocellular, 985-997. See also *Hepatocellular carcinoma*.

Carcinomatosis, in elderly, emergency operation for, 1418

Cardiac disease, in pregnancy, 639-651
counseling in, 640-642
labor and delivery management in, 648

New York Heart Association classification of, 641

Cardiac disorders, in neonatal lupus syndrome, 613
in pregnancy, 646-647
with Behcet's disease, 1241
with dermatomyositis, 1188-1189

Cardiac muscle, contraction of, mechanical basis of, 284-287

Cardiac output, decreased, and orthostatic hypotension, 1341
effect of nitrates on, 363
in measurement of cardiac performance, 291
in pregnancy, 639

Cardiac performance, determinants of, 339
effect of cocaine on, 478-483
measurement of, 290-292

Cardiac toxicity, catecholamine-mediated, beta-blocker therapy for, 374-375

Cardiogenic embolism, and stroke, 1354-1356
treatment of, 1365

Cardiomyopathy, congestive, nifedipine for, 345
dilated, and stroke, 1354
beta-blockers for, 377
ischemic, calcium antagonists for, 341
peripartum, in pregnancy, 646

Cardiorespiratory complications, in amniotic fluid embolus, 735

Cardiovascular alterations, in pre-eclampsia, 625
in pregnancy, 639-640
surgical implications of, 550

Cardiovascular disease, in obesity, 112
inconsistent findings in, 116
risk factors for, exercise and, 217-219
with hypertension, in elderly, 1472

Cardiovascular drugs, 271-516
and liver disease, 779, 787
clinical trials of, 495-509
clinical program of, 506-508
design problems in, 496-506
dose interval in, 507-508
dose response in, 506-507
interactions in, 508
titration in, 501-503
wrong assumptions in, 498-501
wrong incentives for, 497-498
in elderly, disposition of, 487-494
plasma lipid changes with, relevance of, 449-473
positive control studies of, 496-501

Cardiovascular hemodynamics, effects of nifedipine on, 343

Carotid endarterectomy, for stroke prophylaxis, 1363-1364

Carpenter syndrome, and obesity, 166

Catecholamines, chemical structures of, 302
for congestive heart failure, 301-303

increased, in heart failure, beneficial effects of, 374
harmful effects of, 375-376

neurotransmitters of, anorexiant drug action on, 239-241

Catheter, urinary, care of, 1450
problems with, 1446

Catheterization. *See Urinary tract catheterization.*

Causation, in medical liability, definition of, 561-562

Cefazidime, for urinary tract infections, 1445

Ceftriaxone, for urinary tract infections, 1445

Cell-mediated immunity, in primary biliary cirrhosis, abnormalities of, 916-917

Central excitation, cocaine and, 478

Central nervous system, anorexiant drug action on, 239-244
role in falling, 1326, 1329
role in impotence, 1488
role in urinary incontinence, 1424

Ceprofloxacin, for urinary tract infections, 1445

Cerebellar tremor, 1315-1316

Cerebral angiography, in stroke evaluation, 1357-1358

Cerebral cortex, fetal injury to, effects of, 526

Cerebral edema, in fulminant hepatic failure, 959-960

Cerebral infarction, in elderly, 1361-1362

Cerebrospinal fluid, examination of, in acquired cognitive disorder, 1393

Cerebrovascular accident, and urinary incontinence, 1424
with hypertension, in elderly, 1472

Cervical spine, stenosis of, in elderly, 1374

Cesarean delivery, and uterine infection, 713
in maternal diabetes, 694
morbidity with, 520

Charcoal hemoperfusion, for fulminant hepatic failure, 965

Chelation therapy, for hemochromatosis, 840

Chenodeoxycholate, for gallstones, 763

Chicken pox, breastfeeding in, 594

Chilblain lupus, in systemic lupus erythematosus, 1103-1104

Childhood, obesity in, 162

Chlorambucil, cutaneous reactions to, 1292
for primary biliary cirrhosis, 921

Chloroquine, cutaneous reactions to, 1284-1285

Cholangiocarcinoma, in primary sclerosing cholangitis, 1014

Cholangiography, intravenous, 760
percutaneous transhepatic, 761

Cholangiopancreatography, endoscopic retrograde, 760-761, 901-902

Cholangioscopy, peroral, 905-906

Cholangitis, sclerosing, primary, liver transplantation for, 1014-1015

Cholecystitis, in elderly, acute abdomen with, 1416-1418

Cholecystography, oral, 759

Cholechocholithiasis, detection of, imaging for, 901

Cholescintigraphy, 760

Cholestasis, alcohol-induced, 820
chronic, drug-induced, 777
intractable, in primary biliary cirrhosis, 919-920
intrahepatic, of pregnancy, 1043

Cholesterol, effect of aging on, 1525-1526
effect of centrally acting agents on, 462-465
lowering of, 879-882
lovastatin for, 437-448

metabolism of, 438-439
reverse transport of, 282

synthesis of, 756, 864
pathway of, 439

Cholesterol gallstones, risk factors for, 754
therapy for, 762, 765

Cholestyramine, for pruritis, in primary biliary cirrhosis, 920

Choline magnesium trisalicylate, cutaneous reactions to, 1278

Cholinergic hypothesis, of Alzheimer's disease, 1384-1385

Cholinergic receptors, activation of, 1406

Chorionic villus sampling, in fetal diagnosis, 530-531

Chrysiasis, with gold therapy, 1286-1287

Chylomicrons, metabolism of, 438-439
production of, 863

Circumference measurements, and health risks, 119
for body fat determination, 7

Cirrhosis. See also under *Liver disease*.
alcoholic, 818-820
drug-induced, 779-782
in pregnancy, 1044-1045

Cisapride, for chronic constipation, 1506

Citriftein, for hyperalimentation, 1546

Clofibrate, for hypercholesterolemia, 881

Clonazepam, in pregnancy, 664

Clonidine, for hypertension in elderly, efficacy of, 1477
for hypertension in pregnancy, 628-629, 672-674

Clonorchiasis, and hepatocellular carcinoma, 1000-1001

Coagulation factors, circulating, 725

Coagulation studies, in stroke evaluation, 1357

Coagulation system, intrapartum activation of, 727
structure of, 723-724

Coagulopathy(ies), abortion and, 736-737
acquired, 738
acute, in pregnancy, 723-743
consumptive, with intrauterine fetal demise, 732

hereditary, 737-738

in fulminant hepatic failure, 960

neonatal, maternal phenytoin therapy and, 572
with abruptio placentae, 731

with amniotic fluid embolus, 735-736
with septic shock, 735

Coarctation of aorta, in pregnancy, 644

Cocaine, and coronary artery disease, 475-486

cardiovascular complications of, 479-483

chemical structure of, 476

pharmacology of, 475-476

Cognitive disorders, acquired, in elderly, 1383-1411
clinical descriptions of, 1394-1400
evaluation of, 1386-1394, 1407
experimental approach to, 1405-1406
management issues in, 1400-1408
prevention of, 1401

role in falls, 1330

Cognitive factors, in food intake, in obesity, 53
in medical compliance, 1559
in weight control program, 60, 194

Cogwheel phenomenon, in tremor, 1314

Cohen syndrome, and obesity, 166

Colchicine, for leukocytoclastic vasculitis, 1233
for primary biliary cirrhosis, 921

Coleectomy, total, for pyoderma gangrenosum, 1257

Colestipol, lovastatin with, 443

Collagen, deposition of, in systemic sclerosis, 1174
disorders of, penicillamine-induced, 1289-1290

Collagen vascular diseases, 1055-1305
with dermatomyositis, 1185

Colon, cancer of, in obesity, 115
perforated, in elderly, emergency operation for, 1418

Common bile duct, stones in, 767-769
stricture of, biliary stent for, 904

Complement, deposits of, in cutaneous vasculitis, 1226-1227

Comply, for hyperalimentation, 1546

Conceptual age, and effect of drugs in breast milk, 588-589

Confusional state, acute, clinical description of, 1399

Congenital malformations, etiology of, 568
with maternal epilepsy, 663

Congestive heart failure, angiotensin-converting enzyme inhibitors for, 320-322
beta-adrenergic blocking drugs for, 373-385

chronic, digitalis for, 297-300
renin-angiotensin-aldosterone system in, 317-319

endocrine changes in, 315-317

hemodynamics in, effect of nitrates on, 363-365

in hemochromatosis, 837

inotropic agents in, 283-314

neurohumoral changes in, 315-317

nifedipine for, 344

nitrates in, 361-371
effects on mortality, 367-368
rationale for, 361-362
tolerance to, 365-367

pathophysiology of, 292-297, 361-362

Starling curve in, 299

Congophilic angiopathy, stroke vs, 1352

Connective tissue disease, and Raynaud's phenomenon, 1130-1133

mixed, as variant of systemic scleroderma, 1178-1179

lupus band test for, 1270

with leukocytoclastic vasculitis, 1228

Constipation, in elderly, 1497-1509
chronic, stepped-care approach to, 1505-1506
drugs causing, 1499
evaluation of, 1500-1502
management of, 1501
pathophysiology of, 1498-1499
preventive therapy for, 1499-1500
stepped-care approach to, 1502-1505

Consultant. See *Medical consultant*.

Contraception, in diabetes, 696-697
in systemic lupus erythematosus, 606

Contractility, chemical basis of, 286-290

Contraction, mechanical basis of, 284-287
velocity of, 286-287

Contractures, in juvenile dermatomyositis, 1199, 1201

Control, locus of, in obesity, 52

Converting enzymes, inhibition of, humoral effect of, 319-320

Cor pulmonale, in amniotic fluid embolus, 735

Cordocentesis, in fetal diagnosis, 532

Coronary angioplasty, percutaneous transluminal, following thrombolysis, 401-402

Coronary artery disease, cocaine-induced, 475-486
in pregnancy, 646
nifedipine for, 345
risk of, in elderly, lipid levels and, 1525-1530

plasma lipid transport and, 877-879
with myocardial infarction, and congestive heart failure, 293

Cortical collecting tubule, diuretic action in, 274-275

Cortical disorders, testing of, in acquired cognitive disorder, 1390

Corticosteroids, cutaneous reactions to, 1283-1284
fetal effects of, 612
for asthma in pregnancy, 658
for chronic hepatitis B, 972-974
for cutaneous lupus erythematosus, 1068, 1085

for immunosuppression, in liver transplantation, 1026

for juvenile dermatomyositis, 1204-1205

for leukocytoclastic vasculitis, 1232-1233

for lupus erythematosus panniculitis, 1124

for primary biliary cirrhosis, 921

for pyoderma gangrenosum, 1257-1258

Coumarin derivatives, teratogenic effects of, 571-572

Creatinine clearance, in transplanted kidney, in pregnancy, 668

Creatinine-height index, measurement of, in elderly, 1539-1540

Crohn's disease, with pyoderma gangrenosum, 1253

Cromolyn, for asthma in pregnancy, 658

Cryoglobulinemia, with cutaneous necrotizing vasculitis, 1229

Cryptorchidism, in Prader-Willi syndrome, 169

Cushing's syndrome, with corticosteroids, 1283-1284

Cutaneous hypersensitivity, testing of, for nutritional assessment, 1541

Cutaneous immunofluorescence, in collagen vascular diseases, 1263-1274

Cutaneous sclerosis, in systemic scleroderma, 1167

Cutaneous vasculitis, 1221-1235

Cyanosis, in acute asthma, 654
in Raynaud's phenomenon, 1133

Cyclophosphamide, cutaneous reactions to, 1292
fetal effects of, 612

Cyclosporine, and risk of malignancy, 675
cutaneous reactions to, 1292-1293
drug interactions with, 1025
fetal exposure to, 678-679
for immunosuppression, in liver transplantation, 1023-1026
for primary biliary cirrhosis, 921
toxicity of, in pregnancy, 671

Cystitis, with urinary tract catheterization, 1447

Cystometrics, bedside, 1433-1434

Cytomegalovirus, fetal exposure to, 680

Cytotoxic agents, cutaneous reactions to, 1290-1291
for pyoderma gangrenosum, 1258

D-penicillamine, for primary biliary cirrhosis, 921

Damage, in medical liability, definition of, 562

Dapsone, for leukocytoclastic vasculitis, 1233
for pyoderma gangrenosum, 1257

Debridement, for pressure ulcer treatment, 1520-1521

Defensive medicine, practice of, 557

Delayed gratification, in obesity, 51

Delirium, and urinary incontinence, 1426
clinical description of, 1399
diagnostic criteria for, 1395

Delivery, date of, determination of, 523
in cardiac disease, 648
in maternal diabetes, 693-694
premature, delay of, effects of, 522

Delusions, in dementia, treatment of, 1404

Dementia, and urinary incontinence, 1426
causes of, 1392
clinical description of, 1394-1399
degenerative, of Alzheimer's type, 1394-1396
diagnostic criteria for, 1395

intercurrent illness and, 1403
management of, principles in, 1402
multi-infarct, 1396-1398
resuscitation orders in, 1403
reversible, 1401-1402
treatment of, 1403-1405

Denerivation, pharmacologic, cocaine and, 477

Densitometry, of bone minerals, 1458-1459

Dependency, in obesity, 52

Depigmentation, in systemic scleroderma, 1171

Depression, and impotence, 1488-1489
and urinary incontinence, 1427
diagnostic criteria for, 1395

in dementia, treatment of, 1403
in obesity, 49

Deprivation, in obesity, 50

Dermatitis, lupus, photosensitive, 1095-1096

Dermatomyositis, and malignancy, 1211-1220
research findings in, 1212-1214
as systemic disease, 1181-1192
association with pregnancy, 1190-1191
clinical manifestations of, 1212-1213
cutaneous manifestations of, 1181-1182, 1212-1213
diagnosis of, 1182, 1211

genetic predisposition to, 1216

juvenile, 1193-1200
clinical findings in, 1194-1201
cutaneous manifestations of, 1195-1199
diagnosis of, 1203-1204
epidemiology of, 1193-1194
etiology of, 1194
laboratory findings in, 1202
management of, 1204-1207
muscle manifestations of, 1199
pathology of, 1201-1202
prognosis in, 1207
lupus band test for, 1271
tumor types in, 1215

Dermatosis(es), vascular, neutrophilic, 1237-1245

Dermatosis-arthritis syndrome, bowel-associated, 1242

Desferrioxamine, for hemochromatosis, 840

Desipramine, cathartic dosage of, 1504

Detrusor instability, treatment of, 1435

Developmental stage, interaction with environmental teratogen, 568

Diabetes insipidus, nephrogenic, treatment of, 280

Diabetes mellitus, and impotence, 1488
and pregnancy, 685-700
breastfeeding in, 594-597
contraception in, 696-697
in familial hyperlipoproteinemia, 873
in familial hypertriglyceridemia, 872
in hemochromatosis, 836
in obesity, 112, 126, 139
effect of surgery on, 258
etiologic mechanisms of, 127

in Prader-Willi syndrome, 169

in pregnancy, classification of, 687-688
diagnosis of, 687
fetal physiology in, 686
hospitalization vs outpatient care of, 693
management of, 696
obstetric management of, 695-696
lactation in, 595-597

lovastatin for, 444

milk composition in, 594

pregestational, classification of, 687
preconceptual counseling in, 688-689

Diabetic nephropathy, effect of pregnancy on, 688

Diabetic retinopathy, effect of pregnancy on, 689

Dialysis, for fulminant hepatic failure, 963

Diastolic function, effect of calcium antagonists on, 343

Diazepam, in breast milk, 599

Diazoxide, for acute hypertension in pregnancy, 631

DIC. See *Disseminated intravascular coagulation*.

Diclofenac, cutaneous reactions to, 1279

Diet(s), and obesity, 20-22, 171-172
classification of, 204-205
composition of, for elderly, 1535-1536
for hyperlipidemia, 1528
effect on body composition, 232
for obesity, 203-215
in first trimester, in diabetics, 690
low calorie, 205-209
definition of, 203
for obesity, 203-215
types of, 204-205
with behavioral program for obesity, 196
very low calorie, 209-212
complications of, 211
contraindications to, 212
definition of, 203
for obesity, 203-215
monitoring in, 212

Dietary fat, for elderly, 1535-1536
ratio to carbohydrates, role in obesity, 103

Dietary fiber, deficiency of, and constipation, 1500-1503
for elderly, 1535-1536
for weight control, 208, 246

Dietary fluid, in constipation treatment, 1503

Diethylstilbestrol, teratogenic effects of, 575-576

Diflunisal, cutaneous reactions to, 1278

Digital arteries, narrowing of, in Raynaud's phenomenon, 1129

Digital ulcers, in systemic scleroderma, 1167

Digitalis, 297-300
clinical response to, 300
effect on Starling curve, 299
hemodynamic effects of, 300
in breast milk, 601
inotropic effects of, 299

Digoxin, loading dose of, 298
nifedipine vs, 348-349
pharmacokinetics of, 297-298
toxicity of, 298-299

Dihydropyridines, second-generation, for heart failure, 351-353

Diltiazem, effect on heart rate, 342
for acute myocardial infarction, clinical studies of, 427-429
results with, 430
nifedipine vs, 350-351

Diphenylhydantoin, for weight control, 243

Disc herniation, in elderly, 1375

Disclosure, physician's duty of, 559

DISH. See *Skeletal hyperostosis, diffuse idiopathic*.

Disseminated intravascular coagulation, amniotic fluid embolus and, 735-736
causes of, 730-737
eclampsia and, 736

fetal, in multiple gestations, 734
hemolytic uremic syndrome and, 737
in pregnancy, 727-737
diagnosis of, 728
management of, 728-729
trigger mechanisms for, 730-737

pre-eclampsia and, 736

sepsis and, 734-735
with abruptio placentae, management of, 731
with intrauterine fetal demise, 732-734

Distal tubule, diuretic action in, 274-275

Disulfiram, and liver disease, 788

Diuretics, 271-282
clinical trials of, titration in, 501
for hypertension, in elderly, 1475-1476
in pregnancy, 628
in breast milk, 600
loop, 273-274, 277
nonthiazide, effect on serum lipids, 454
pharmacology of, nephron physiology and, 272
physiology of, new directions in, 280-281
plasma lipid changes with, 450-453
side effects of, 278
sites of action of, 271-275
therapy with, consequences of, 272
issues in, 275-276

Diverticulitis, in elderly, acute abdomen with, 1416-1417

Dobutamine, for congestive heart failure, 303

Dopamine, for congestive heart failure, 302

Dopaminergic medication, for Parkinson's disease, 1313

Doppler ultrasound, in fetal diagnosis, 533-534

Dose-response relationship, interaction with environmental teratogen, 568

Doxepin, cathartic dosage of, 1504

Dressings, for pressure ulcer treatment, 1521

Drop attacks, role in falls, 1329

Drug trials, clinical, dose intervals in, 507-508
dose-response in, 506-507
design problems in, 496-506
drug toxicity in, 502
ethical considerations in, 505-506
interactions in, 508
statistical analysis of, failure of, 497
wrong assumptions in, 498-501
wrong incentives for, 497-498

Drugs, allergy to, signs of, 784
and constipation, 1499
and hepatocellular carcinoma, 1003-1006
and impotence, 1487-1488
and tremor, 1316
and urinary incontinence, 1427
as cause of obesity, 172-173

Drugs (*Continued*)

- clearance of, in elderly, 488
- effectiveness of, determination of, 498
- effects on fetus, 570, 611-613
- effects on nutrient absorption, 1533
- for hepatic encephalopathy, 807
- for obesity, 237-249
- in elderly, response to, mechanisms of, 487-491
- in lactation, 588-589
- interaction with environmental teratogen, 568
- metabolism of, alcohol and, 786
- and liver disease, 785-786
- noncompliance with, in elderly, 1554, 1557
- oral nonbioavailability of, 590
- placental transport of, 569
- role in falls, 1329
- Duodenal ulcer, in elderly, acute abdomen with, 1416
- Duty, in medical liability, definition of, 558-559
- Dyslipoproteinemia, 871-872
- in obesity, effect of surgery on, 258
- Dysphagia, in dermatomyositis, 1183, 1189
- Dyspnea, in acute asthma, 655
- Ear, in discoid lupus erythematosus, 1056, 1059
- Eating. See *Food intake*.
- Eating style, in obesity, 54-56
- Eclampsia, and disseminated intravascular coagulation, 736
- and liver dysfunction, 1044
- seizures in, 626, 662
- Eisemenger's syndrome, in pregnancy, 645
- Ejection fraction, following thrombolytic therapy reperfusion, 398
- in measurement of cardiac performance, 291
- Elastosis perforans serpiginosa, penicillamine-induced, 1290
- Elderly. See also *Aging*.
- acute abdomen in, 1413-1422
- cardiovascular drugs in, disposition of, 487-494
- cognitive disorders in, 1383-1411
- coronary heart disease risk in, 1525-1530
- falls in, 1321-1336
- hypertension in, 1471-1481
- medication compliance in, 1551-1563
- nutrition in, 1531-1549
- orthostatic hypotension in, 1337-1349
- osteoporosis in, 1455-1470
- pressure ulcers in, 1511-1524
- propranolol use in, 489-491
- rheumatic syndromes in, 1371-1381
- sexual function in, 1483-1495
- stroke in, 1351-1369
- tremors in, 1307-1319
- urinary incontinence in, 1423-1439
- urinary tract catheterization in, 1441-1454
- Electrocardiogram, in acute abdomen, 1415-1416
- Electroencephalography, for hepatic encephalopathy, 795-796
- in acquired cognitive disorder, 1393
- in stroke evaluation, 1356
- Electrolytes, altered, in acute abdomen, 1415-1416
- disorders of, in fulminant hepatic failure, 961
- effects of angiotensin-converting enzyme inhibitor on, 323-325
- monitoring of, in hyperalimentation, 1547
- patterns of excretion of, 271-275
- Electromyography, in dermatomyositis, 1184-1185
- Embryopathy, warfarin, 571
- Emotional stress, in renal transplant patients, in pregnancy, 675
- Enalapril, adverse effects of, 330-331
- clinical efficacy of, 326
- decreased serum sodium with, 323
- effects on serum potassium, 325
- for chronic congestive heart failure, hemodynamic effects of, 320
- renal effects of, 324
- side effects of, 330
- Encephalitis, clinical description of, 1399-1400
- Encephalopathy, hepatic, 793-813. See also *Hepatic encephalopathy*.
- Endocarditis, bacterial, prophylaxis for, at delivery, 648
- Endocrine disorders, and impotence, 1488 and obesity, 113, 139-160
- and urinary incontinence, 1427
- Endocrine pancreas, in obesity, 139-141
- Endometrial cancer, in obesity, 114
- Endometritis, 714-715
- Endoscopy, emergency, in esophageal varices, 944
- techniques of, advanced, 895-909
- Enemas, for chronic constipation, 1506
- Energy expenditure, and body weight set-point, 17-19
- effect of chronic exercise on, 227-233
- elements of, 97-100
- for recreational activities, 1534
- genetics and, 75
- in body weight regulation, 15-17
- in elderly, 1541-1542
- in obesity, 69, 97-110, 219-227
- limits of, 97-100
- Energy intake, genetics and, 75
- in body weight regulation, 15-17

Enigmatic fever, pelvic vein thrombophlebitis in, 717

Ensure, for hyperalimentation, 1546

Enteral hyperalimentation, for protein-calorie malnutrition, 1544 products for, 1545

Environment, role in falls, 1328, 1333

Enzyme inhibitors, for weight control, 246

Eosinophilia, in localized scleroderma, 1149-1150

Eosinophilic fasciitis, 1157-1166. See also under *Fasciitis*.

Ephedrine, for weight control, 244

Epilepsy, breastfeeding in, 598-599 in pregnancy, 661-665

Epinephrine, for acute asthma in pregnancy, 656

Episiotomy infection, life-threatening, 718-719

Erectile dysfunction. See *Impotence*.

Erythema, periungual, in systemic lupus erythematosus, 1103

Erythema nodosum, 1242-1243

Esophageal varices, hemorrhage of, 941-947 management of, 943-945 mechanism of, 941-943 prevalence of, 940 prevention of, 945-947 prognosis in, 943 natural history of, 941-943 pharmacologic therapy of, 946 pressure measurement of, 939-940 surgery for, 945

Essential tremor, in elderly, 1310-1312 Parkinsonian signs in, 1315

Estrogen, and hepatocellular carcinoma, 1003-1004 and sexual function, in aging females, 1492 for osteoporosis, 1462-1464 in pregnancy, effect on seizure disorders, 661 effect on systemic lupus erythematosus, 606

Ethanol, metabolism of, 815-816

Ethical considerations, in drug trials, 505-506

Ethosuximide, in breast milk, 599

Euglycemia, in diabetes, maintenance during delivery, 695

Evoked responses, for hepatic encephalopathy, 795-796

Exercise, and cardiovascular disease risk factors, 217-219 and obesity, 217-236 and thermic effect of food, 101, 223-227 effects of, 227-233 on body composition, 232 on food intake, 228-230 psychological, 233 thermic, 97

energy expenditure in, 221-223, 228 for hypertension in elderly, 1474 for orthostatic hypotension, 1345 for osteoporosis, 1465-1466 improved capacity for, with angiotensin-converting enzyme inhibitors, 326 in weight control program, 107, 193 techniques of, 191 tolerance for, in congestive heart failure, effect of nitrates on, 363-365

Exercise training, effects of, 227-228, 230-233

Expert witness, in malpractice case, role of, 561

Extracorporeal shock wave lithotripsy, for gallstones, 765-766

Eyesight, changes in, role in falling, 1326-1327

Falls, in elderly, 1321-1336 aging process and, 1324-1327 clinical approach to, 1330-1333 death from, 1321-1322 epidemiology of, 1321-1323 etiology of, 1327-1330 sequelae to, 1323-1324 treatment of, 1333-1334

Familial Mediterranean fever, 1243

Fasciitis, eosinophilic, 1157-1166 as variant of systemic scleroderma, 1177 biopsy for, 1162 clinical features of, 1158-1161 course of, 1163 cutaneous manifestations of, 1158-1159 etiology of, 1163-1164 extracutaneous manifestations of, 1158-1159 hematologic associations with, 1160-1161 laboratory findings in, 1161 localized scleroderma vs, 1151-1152 pathology of, 1162-1163 therapy for, 1163 visceral involvement in, 1160 necrotizing, postpartum, signs of, 718

Fat, dietary, for elderly, 1535 role in obesity, 103 distribution of, in obesity, 162 percentiles for, 164 regional, for measurement of overweight, 175

regional, mobilization of, 248 storage of, factors promoting, 103-105 total body, 31 topography of, definition of, 68

Fat cells, 83-96. See also *Adipose tissue*. number of, for measurement of overweight, 175

Fat cells (*Continued*)
 number of, in obesity, 161–162
 nutritional regulation of, 90
 size of, for measurement of overweight, 175
 nutritional regulation of, 89–90

Fat-to-carbohydrate ratio, in diet, role in obesity, 103

Fatty acids, in adipose tissue, 84

Fatty liver, alcoholic, 817–818
 of pregnancy, 1043–1044

and disseminated intravascular coagulation, 737

Feedback signals, of nutrient balance, 34–36

Feeding. See *Food intake*.

Feeding formulas, for protein-calorie malnutrition, 1544

Felodipine, for heart failure, 352–353

Females, sexual function in, with aging, 1491–1492

Fenoprofen, cutaneous reactions to, 1280

Ferric molecules, uptake of, mechanisms of, 835

Ferritin, serum levels of, in hemochromatosis, 834

Fertility, in human immunodeficiency virus infection, 703
 in systemic lupus erythematosus, 605–606

Fetal AIDS syndrome, 704

Fetal alcohol syndrome, 571

Fetal assessment, biochemical, 535–536
 technology of, 529–538

Fetal death, definition of, 518
 intrauterine, and disseminated intravascular coagulation, 732–733
 with maternal renal transplant, 675–676
 with maternal systemic lupus erythematosus, 608

Fetal distress, in labor, prediction of, 538

Fetal heart rate, and fetal status, 536

Fetal hydantoin syndrome, 572

Fetal monitoring, electronic, external, 536–537
 in diabetes, in third trimester, 692–693

Fetal movement, maternal perception of, 536

Fetal trimethadione syndrome, 573

Fetal valproate syndrome, 573

Fetor hepaticus, in hepatic encephalopathy, 796

Fetus. See also under *Fetal*.
 as patient, 517–540
 drug effects on, 570
 effect of maternal disease on, 546
 high-risk index for, 527–529

Fever, enigmatic, pelvic vein thrombophlebitis in, 717
 in pyogenic liver abscess, 849
 persistent, in endometritis, 715–716

Fiber, dietary, for weight control, 208, 246

Fibrin, deposits of, in cutaneous vasculitis, 1226–1227

Fibrinogen, in coagulation system, 724
 levels of, with thrombolytic therapy, 395

Fibrinolytic agents, for Raynaud's phenomenon, 1138–1139

Fibrinolytic system, activity of, 727

Filling pressures, in cardiac performance, 291

Fludrocortisone, for orthostatic hypotension, 1345

Fluid intake, in elderly, 1533–1534

Fluid retention, in hepatic encephalopathy, 796

Fluid therapy, for acute asthma in pregnancy, 657

Fluoride, for osteoporosis, 1466

Flurbiprofen, cutaneous reactions to, 1281

Foam pads, for pressure ulcer treatment, 1517

Food, caloric density of, in obesity, 56
 intake of. See *Food intake*.
 thermic effect of, exercise and, 97, 101, 223–226

Food intake, control of, for obesity, 53–54
 in humans, 29–45
 effect of exercise on, 228–230
 in obesity, 53–55, 103, 171
 relationship to fat cell size, 89
 signals affecting, 34, 37
 thermic response to, 100

Foot care, fall prevention by, 1333

Forgetfulness, benign senescent, 1387

Formula diets, for obesity, 295, 208–209

Fractures, in elderly, 1372
 with falls, 1323
 in osteoporosis, prevention of, 1456

Free radical scavengers, for alcoholic liver disease, 825

Friction, and pressure ulcers, 1514

Froment's sign, in tremor, 1314

Functional assessment, in acquired cognitive disorder, 1388, 1391

Functional residual volume, in pregnancy, 654

Furosemide, for hypercalcemia, 278–279
 for hyponatremia, 280

GABA/benzodiazepine receptor complex, in hepatic encephalopathy, 802–804

Gait, in elderly, effect on falling, 1325–1326, 1332

Galactogenesis, initiation of, 586

Galactopoiesis, in lactation, 584

Gallstones, computed tomography of, 760
 diagnosis of, 758–761
 environmental factors in, 754
 epidemiology of, 753–754

formation of, 757-758
 imaging of, 899-901
 laser lithotripsy of, 906
 oral therapy for, 762-764
 pathophysiology of, 754-758
 recurrence and prevention of, 769
 therapy for, 761-769, 906
 types of, 753

Gangrene, digital, in systemic lupus erythematosus, 1104
 postpartum, 718-719

Gastric bypass, complications of, 260
 for weight control, 256-257

Gastric emptying, inhibitors of, for weight control, 247

Gastric paresis, in diabetes, effect of pregnancy on, 689

Gastric restriction, in weight control, 254

Gastrointestinal alterations, in pregnancy, surgical implications of, 550

Gastrointestinal disorders, in Behcet's disease, 1241
 in cutaneous vasculitis, 1226
 in dermatomyositis, 1189-1190
 in juvenile dermatomyositis, 1200
 in systemic scleroderma, 1171-1172

Gastrointestinal signals, of nutrient balance, 35

Gastrointestinal tract, drugs affecting, for weight control, 245-247

Gastropathy, portal hypertensive, 947

Gastroplasty, for weight control, 253, 257

Gemfibrozil, for hypercholesterolemia, 881
 for hyperlipidemia, 1528

Genetic diseases, liver transplantation for, 1016-1017

Genetic theory, of Alzheimer's disease, 1385

Genetics, and adaptation to chronic overfeeding, 76-78
 and body fat, 71-75
 and energy expenditure, 75
 in obesity, 67-81, 165-169

Genital tract infection, in pregnancy, 713

Geriatric medicine, 1307-1563

Gestational age, as predictor of morbidity and mortality, 523
 ultrasonic determination of, 524

Glomerular filtration rate, in congestive heart failure, 323
 in pregnancy, 669-671

Glucagon, for alcoholic liver disease, 825

Glucocorticoids, for acute asthma in pregnancy, 657
 for alcoholic liver disease, 824

Glucose, effect of body fat distribution on, 122-126

Glucose tolerance, abnormal, in familial hypertriglyceridemia, 872
 and cardiovascular disease risk factors, 218

Glycemic control, in first trimester, in diabetics, 689-690

Gold, cutaneous reactions to, 1285-1288

Gorging, nibbling vs. in lipogenesis, 105

Gottron's papules, in dermatomyositis, 1181, 1183, 1212
 in juvenile dermatomyositis, 1195, 1197

Graft rejection, in liver transplantation, 1024

Granulomatosis, allergic, with cutaneous granulomatous vasculitis, 1230

Graves' disease, breastfeeding in, 597

Growth hormone, for weight control, 245
 reduced, in obesity, 141-143, 170

Guarding, involuntary, in acute abdomen, 1414

Gut, changes in, age-related, 1498-1499

Gynecologic tumors, in dermatomyositis, 1214

Hallucinations, in dementia, treatment of, 1404

Halothane, metabolism of, and liver disease, 785-786

Harm, in medical liability, definition of, 562

Head trauma, and tremor, 1316

Health risks, of obesity, 111-138
 inconsistent findings in, 115-118

Heart. See also under *Cardiac*; *Cardio-Cardiopathy*.
 Heart disease, breastfeeding in, 599-601
 congenital, in pregnancy, 643-644
 Heart failure, angiotensin-converting enzyme inhibitors in, 315-338
 beta-blockers for, 377
 calcium antagonists and, 339-359
 congestive. See *Congestive heart failure*.
 Heart muscle, effect of cocaine on, 478-483
 microscopic structure of, 285

Heart rate, effect of calcium antagonists on, 342-343
 effect of cocaine on, 479
 in acute asthma, 655

Heart valves, prosthetic, and stroke, 1354
 in pregnancy, 647-648

Height, change in, in elderly, 1537
 in body fat determination, 3

Heliotrope rash, in dermatomyositis, 1181, 1183, 1212
 in juvenile dermatomyositis, 1196

Hemangioma, cavernous, imaging of, 900

Hematologic abnormalities, in neonatal lupus syndrome, 613
 with dermatomyositis, 1190

Hematologic alterations, in pregnancy, surgical implications of, 550

Hematologic malignancy, with pyoderma gangrenosum, 1254

Hematoma, with recombinant tissue-type plasminogen activator therapy, 394

Hematuria, in cutaneous vasculitis, 1225

Hemochromatosis, 831-845

- and hepatocellular carcinoma, 1003
- idiopathic, 832-836
- liver transplantation for, 1017
- secondary, 838-839
- therapy for, 839-840

Hemodialysis, and secondary hemochromatosis, 838

Hemolytic uremic syndrome, and disseminated intravascular coagulation, 737

Hemophilia, coagulopathy in, 738

- liver transplantation for, 1017

Hemorrhage, in stroke, 1352

- intracerebral, treatment of, 1365-1366
- postpartum, with abruptio placentae, 732
- with thrombolytic therapy, 395

Hemosiderosis, in hemochromatosis, 832

Henle's loop, thick ascending limb of, diuretic action in, 273

Henoch-Schonlein purpura, as hypersensitivity vasculitis, 1229

Heparin, for stroke, 1362-1363

- in thrombolytic therapy, 391

Hepatic. See also *Liver*.

Hepatic diseases, 753-1053

Hepatic encephalopathy, 793-813, 943, 959

- acute, clinical staging of, 959
- treatment of, 805
- assessment of, 794-796
- associated findings in, 796-797
- diet for, 806-807
- etiology of, 797
- laboratory tests of, 795
- manifestations of, 793
- neuropathology of, 799
- pathogenesis of, 800-804
- precipitating factors in, 797-798
- prognosis in, 798-799
- stages of, 794
- treatment of, 804-807

Hepatic enzymes, elevation of, drug-induced, 776

Hepatic failure, acute, definition of, 955-956

- degree of, assessment of, 943
- fulminant, 955-970
- complications of, 959-962
- course of, 965-966
- definition of, 955-956
- etiology of, 956-957
- liver transplantation for, 1019-1020
- management of, 962-966
- pathology of, 957-959
- prognosis in, 966-967

Hepatic vein, catheterization of, for portal pressure measurement, 937

thrombosis of, liver transplantation for, 1018-1019

Hepatitis, alcoholic, 817-819

- antigens of, in hepatocellular carcinoma, 986
- breastfeeding in, 593
- chronic, alcohol-induced, 820-821
- and hepatocellular carcinoma, 999-1000
- differential diagnosis of, 972
- liver transplantation for, 1015-1016
- delta, 978-979
- drug-induced, frequency of, 776
- viral, and fulminant hepatic failure, 956
- chronic, 971-983
- in pregnancy, 1041-1043
- nonA, nonB, 979-980

Hepatitis B, chronic, acyclovir for, 976

- combination therapy for, 977-978
- corticosteroids for, 972-974
- interferon for, 974-975
- levamisole for, 976
- liver transplantation for, 1015
- prednisone for, 978
- ribavirin for, 976
- transfer factor for, 977
- treatment of, 971-972
- vidarabine for, 975

Hepatitis B virus, and hepatocellular carcinoma, 985

- DNA of, integrated, 991-992
- genomic DNA map of, 987-988

Hepatitis D virus, 978-979

Hepatobiliary dysfunction, following liver transplantation, 1027-1029

Hepatocellular carcinoma, 985-997

- alcohol-induced, 821
- conditions associated with, 999-1009
- growth of, 992-993
- hepatitis B virus-related, 986-991
- pathogenesis of, 989-993
- liver transplantation for, 1017-1018
- risk factors for, 991
- with primary biliary cirrhosis, 912

Hepatocellular necrosis, acetaminophen-induced, 958

- in fulminant hepatic failure, 957

Hepatoma cell line, analysis of, 990

Hepatomegaly, in pyogenic liver abscess, 849

Hepatorenal syndrome, liver transplantation for, 1018

Hepatosplenomegaly, in familial hyperlipoproteinemia, 873

Hepatotoxins, acute, classification of, 780-781

- clinical syndromes caused by, 776
- idiosyncratic, and liver disease, 784-785
- intrinsic, and liver disease, 783-784

Heredity. See *Genetics*.

Hernia, incarcerated, in elderly, acute abdomen with, 1416-1418

Herpes encephalitis, clinical description of, 1399

Herpes simplex, breast-feeding in, 593-594
 High-fiber diets, for obesity, 204, 207-208
 High-protein diets, for obesity, 205
 Hip fracture, and pressure ulcers, 1513
 incidence of, 1456
 Holter monitoring, in stroke evaluation, 1357
 Hormones, derivatives of, and liver disease, 778
 for weight control, 247-248
 imbalances of, in obesity, 127
 in nutrient balance, 35
 levels of, in female obesity, 145
 in male obesity, 143-144
 Human chorionic gonadotropin, for obesity, 247
 Human immunodeficiency virus, fetal exposure to, 679-680
 infection with. See *Human immunodeficiency virus infection*.
 prenatal screening for, 707-708
 Human immunodeficiency virus infection, breastfeeding in, 593
 in pregnancy, 701-711
 care of, 706-707
 effect of pregnancy on, 705-706
 effect on pregnancy, 703-705
 seroprevalence of, 702-703
 perinatal transmission of, 703-705
 pregnancy prevention in, 706
 Humoral immunity, abnormalities of, in primary biliary cirrhosis, 916
 Hyaline degeneration, in lupus erythematosus panniculitis, 1117-1119
 Hydralazine, for hypertension in pregnancy, 630-631, 672-674
 nifedipine vs, 348
 Hydrocephalus, normal pressure, and urinary incontinence, 1424
 dementia in, 1398-1399
 Hydrochlorothiazide, and subacute cutaneous lupus erythematosus, 1087
 plasma lipid changes with, relevance of, 450
 Hydroxychloroquine, cutaneous reactions to, 1284-1285
 for eosinophilic fasciitis, 1163
 for subacute cutaneous lupus erythematosus, 1085
 Hyperalimentation, for protein-calorie malnutrition, 1544
 assessment of, 1547
 Hyperbilirubinemia, in infants of diabetic mothers, 687
 Hypercalcemia, furosemide for, 278-279
 Hypercalcuria, idiopathic, thiazides for, 278
 Hypercholesterolemia, 1527-1529
 familial, 869-870
 lovastatin for, 442-444
 polygenic, 871
 Hypergammaglobulinemia, in localized scleroderma, 1150
 Hyperglycemia, in hemochromatosis, 836
 in obesity, 141
 monitoring of, in hyperalimentation, 1547
 thiazide-induced, 450
 Hyperinsulinemia, in hemochromatosis, 836
 in obesity, 139, 170
 Hyperlipidemia, multiple lipoprotein-type, 870-871
 thiazide-induced, 450
 treatment of, 1528
 Hyperlipoproteinemia(s), 859-893
 classification of, 865
 combined, 870-871
 familial, 871-874
 laboratory testing for, 875-877
 lipoprotein patterns in, classification of, 867
 primary, 866-874
 secondary, 874-875
 diseases associated with, 869
 treatment of, 879-882
 Hyperosmotic agents, for chronic constipation, 1505-1506
 Hyperparathyroidism, in obesity, 148
 Hyperpigmentation, in hemochromatosis, 836
 with gold therapy, 1287
 Hypertension, and impotence, 1487
 and lacunar infarction, 1353
 breastfeeding in, 599-601
 chronic, pre-eclampsia vs, 624
 definition of, 623
 drugs for, clinical trials of, 501
 in elderly, 1471-1481
 incidence of, 1471-1472
 isolated systolic, 1473
 nonpharmacologic therapy of, 1474
 pathophysiology of, 1472-1473
 pharmacologic therapy of, 1474-1475
 adverse effects of, 1477-1478
 prevalence of, 1471-1472
 risks of, 1472
 treatment recommendations for, 1479
 in obesity, 149
 effect of surgery on, 258
 in pregnancy, crisis in, 623-638
 in renal transplant patients, 672-674
 therapy of, 628-634
 medication compliance in, 1553
 portal, 931-953
 classification of, 934
 diagnostic approach to, 947-948
 drug-induced, 782
 drugs for, 946
 etiology of, 931-933
 gastropathy in, 947
 nonvariceal bleeding in, 947
 pathophysiology of, 932-935

Hypertension (*Continued*)
 portal, patient evaluation in, 935-941
 therapeutic approach to, 947-948
 systemic, myocardial infarction prevention in, 410-411
 therapy of, diuretics in, 277-278

Hyperthyroidism, breastfeeding in, 597

Hypertriglyceridemia, familial, 872-873

Hyperuricemia, in familial hyperlipoproteinemia, 873

Hyperventilation, for fulminant hepatic failure, 963
 in pregnancy, 653

Hypoalbuminemia, and pressure ulcers, 1513
 in protein-calorie malnutrition, 1543
 in pyogenic liver abscess, 849

Hypoaldosteronism, primary, in hemochromatosis, 837

Hypocalcemia, in infants of diabetic mothers, 687

Hypofibrinogenemia, with intrauterine fetal demise, 732-733

Hypoglycemia, in fulminant hepatic failure, 961
 in infants of diabetic mothers, 686

Hypogonadism, in hemochromatosis, 836
 with aging, 1484

Hyponatremia, development of, diuretics and, 276
 treatment of, 279-280

Hypotension, autonomic, in elderly, treatment of, 1344-1346
 in fulminant hepatic failure, 960
 orthostatic, in elderly, 1337-1349
 age as risk factor for, 1340-1341
 atypical syndromes of, management of, 1346-1347
 criteria for, 1338
 differential diagnosis of, 1341-1342
 epidemiology of, 1337-1338
 evaluation of, 1343-1344
 medications associated with, 1343
 with angiotensin-converting enzyme inhibitors, 330
 with nifedipine, 346
 with thrombolytic therapy, 395

Hypothalamic obesity, 22-23, 172

Hypothalamic-pituitary-adrenal axis, in obesity, 146-147

Hypothalamic-pituitary-testicular axis, changes with aging, 1485

Hypothyroidism, breastfeeding in, 597
 with primary biliary cirrhosis, 913

Hypovolemia, in esophageal varices, 944
 in fulminant hepatic failure, 960

Hypoxemia, arterial, in fulminant hepatic failure, 961

Hypoxia, fetal sensitivity to, 525

Hysterectomy, and sexual function, in aging females, 1492

Hysterical tremor, 1317

Ibuprofen, cutaneous reactions to, 1280

Idiopathic thrombocytopenic purpura, in pregnancy, case history of, 553-554

Immobility, and pressure ulcers, 1513

Immune complexes, in vasculitis, 1223

Immune disorders, in dermatomyositis, with malignancy, 1216
 in juvenile dermatomyositis, 1194
 in leukocytoclastic vasculitis, 1228
 in primary biliary cirrhosis, 916-917
 in systemic scleroderma, 1174

Immunity, cell-mediated, in pyoderma gangrenosum, 1251-1252

Immunofluorescence, cutaneous, in collagen vascular diseases, 1263-1274
 direct, preparation of, 1264
 in pyoderma gangrenosum, 1251

Immunoglobulins, elevated, in leukocytoclastic vasculitis, 1231
 in primary biliary cirrhosis, 913
 in chronic cutaneous lupus erythematosus, 1065-1066, 1265

Immunosuppressive agents, and liver disease, 779
 fetal exposure to, 676
 for pyoderma gangrenosum, 1258
 for systemic scleroderma, 1176
 for systemic vasculitis, 1233

Impotence, with aging, 1485-1489
 drugs associated with, 1488-1489
 etiology of, 1486-1489
 management of, 1489-1491

Inactivity, and obesity, 170-171

Indomethacin, cutaneous reactions to, 1278

Infant mortality, definition of, 518

Infection, and hepatocellular carcinoma, 999-1001
 and urinary incontinence, 1427
 following liver transplantation, 1030-1032
 in fulminant hepatic failure, 961
 in renal transplant patients, in pregnancy, 674-675
 protection against, breastfeeding and, 583
 severe, in pregnancy, 713-721
 with cutaneous necrotizing vasculitis, 1228

Infection theory, of Alzheimer's disease, 1386

Infectious disease, breastfeeding in, 591-594

Inflammatory bowel disease, in primary sclerosing cholangitis, 1014

Informed consent, in medical liability, 558
 standards of, 560

Inhalers, for asthma in pregnancy, 658

Inotrope(s), chemical structure of, 294
 classes of, 295
 definition of, 283
 effects of, measurement of, 292
 for congestive heart failure, 283-314
 in muscle contraction, 289-290
 nondigital, 301-307
 pharmacologic, action of, 293-297
 Insomnia, in dementia, treatment of, 1404
 Inspiratory reserve volume, in pregnancy, 654
 Insulin, and nutrient balance control, 38
 dynamics of, body fat distribution and, 122-123
 for alcoholic liver disease, 825
 for diabetic patient, 696
 during delivery, 695
 in first trimester, 690
 resistance to, in obesity, 140
 role in lactation, 586
 sensitivity to, and cardiovascular disease
 risk factors, 218
 Insulin-like growth factor I, in adipocyte differentiation, 92
 Interferon(s), for chronic hepatitis B, 974-975
 for hepatic encephalopathy, 807
 Internal malignancy, with pyoderma gangrenosum, 1254
 Interstitial lung disease, with dermatomyositis, 1186-1188
 intestinal bypass, complications of, 260-261
 for weight control, 253
 Intestinal obstruction, in elderly, acute
 abdomen with, 1416-1418
 Intestinal transit time, in constipation, 1498-1499
 Intracranial pressure, increased, in fulminant hepatic failure, 959-960
 Intrahepatic duct, stones in, 767-769
 Intrauterine fetal demise, and disseminated intravascular coagulation, 732-734
 Iodine, radioactive, teratogenic effects of, 575
 Iron, accumulation of, pathways of, 835
 Ischemia, beta-blockers for, 415-416
 in stroke, 1352-1356
 Ischemic cardiomyopathy, calcium antagonists for, 341
 Isoniazid, metabolism of, and liver disease, 786
 Isoproterenol, for acute asthma in pregnancy, 657
 for congestive heart failure, 301
 Isosorbide dinitrate, for congestive heart failure, 364-365
 nifedipine vs, 347
 Isotestin HN, for hyperalimentation, 1545
 Isotretinoin, teratogenic effects of, 576
 Isradipine, for heart failure, 353
 Jakob-Creutzfeldt disease, dementia in, 1398
 Jaundice, drug-induced, 776
 in hepatic encephalopathy, 796
 in primary biliary cirrhosis, 911
 obstructive, and secondary hyperlipoproteinemia, 874
 Jejunostomy bypass, for weight control, 255
 Jejunoileal bypass, for weight control, 255
 Jejunoileal bypass, for hyperalimentation, 1545
 Joint disorders, in dermatomyositis, 1186
 in eosinophilic fasciitis, 1159
⁴K counting, for body fat determination, 2
 Kallikrein-kinin system, 317
 Ketoacidosis, in diabetes, in third trimester, 692
 Ketogenic diets, for obesity, 207
 Ketoprofen, cutaneous reactions to, 1281
 Kidney, alterations in, in pregnancy, surgical implications of, 550
 dysfunction of, following liver transplantation, 1033
 effects of angiotensin-converting enzyme inhibitor on, 323-325
 function of, and clinical efficacy of angiotensin-converting enzyme inhibitors, 327, 330
 testing of, in first trimester, in diabetes, 690
 Kidney disease, in dermatomyositis, 1190
 in leukocytoclastic vasculitis, 1231
 in subacute cutaneous lupus erythematosus, 1079
 in systemic scleroderma, 1172
 progression of, in pregnancy, 671
 Kidney failure, acute, diuretics in, 275-276
 in fulminant hepatic failure, 961
 Kidney transplant patients, pregnancy counseling of, 680-681
 pregnancy outcome in, 675-676
 Korsakoff's syndrome, clinical description of, 1399
 Labetolol, effect on plasma lipids, 457
 effect on serum lipids, 461
 for hypertension in pregnancy, 629-630, 672-674
 Labor, management of, in cardiac disease, 648
 premature, tocolytic therapy for, 524
 Lactation, drugs in, 588-589
 energy utilization in, 586-587
 enhancement of, drugs for, 590
 in diabetics, insulin dosage during, 595
 medical illness in, general management of, 588-591
 physiology of, 584-588
 suppression of, drugs for, 590

Lactitol, for hepatic encephalopathy, 806
 Lactogenesis, in lactation, 584
 Lactulose, for chronic constipation, 1504, 1506
 for fulminant hepatic failure, 962
 for hepatic encephalopathy, 806
 Lacunar infarction, in stroke, 1353-1354
 treatment of, 1365
 Language, testing of, in acquired cognitive disorder, 1390
 Latex catheters, for urinary tract catheterization, 1442
 Laxatives, irritant, avoidance in constipation, 1502
 cathartic dosage of, 1504
 classes of, 1499, 1502
 Left-to-right shunts, in pregnancy, 644
 Left ventricular afterload, effect of calcium antagonists on, 340
 Left ventricular dysfunction, nifedipine for, 345, 347
 Left ventricular work, in cardiac performance measurement, 291
 Legal liability, of medical consultant, in pregnancy, 557-565
 Lethargy, in dementia, treatment of, 1405
 Leukocytoclasia, in Sweet's syndrome, 1238
 Leukocytosis, in pyogenic liver abscess, 849
 Leukoderma, vitiligo-like, in subacute cutaneous lupus erythematosus, 1076
 Leukopenia, neonatal, azathioprine and, 677-678
 Levamisole, for chronic hepatitis B, 976
 Lichen planus, basement membrane zone band in, 1265
 with systemic lupus erythematosus, 1107
 Lichen planus-like lesions, penicillamine-induced, 1288-1289
 with gold therapy, 1286-1287
 Lichen sclerosus et atrophicus, with localized scleroderma, 1147
 Lifestyle techniques, in weight control program, 191
 Lipemia, post alimentary, high density lipoproteins and, 878
 Lipids, abnormalities of, drug selection considerations with, 467
 and cardiovascular disease risk factors, 218
 levels of, and risk of atherosclerotic coronary heart disease, in elderly, 1525-1530
 in obesity, 149
 mobilization from adipocytes, control of, 84
 plasma, drug effect on, calculations of, 467
 serum, effect of alpha-blockers on, 464
 effect of atenolol on, 458
 effect of beta-blockers on, 459, 460
 effect of labetolol on, 461
 effect of metoprolol on, 456
 effect of nonthiazide diuretics on, 454
 effect of prazosin on, 463
 effect of propranolol on, 455
 effect of thiazides on, 452
 Lipoatrophy, in lupus erythematosus pan-niculitis, 1116
 Lipogenesis, from excess carbohydrates, 104
 nibbling vs gorging in, 105
 regulation of, 85
 Lipolysis, regulation of, 86
 Lipoprotein(s), and cardiovascular disease
 risk factors, 218
 electrophoresis of, 875
 high density, metabolism of, 865
 protection from atherosclerosis by, 878
 high density, lovastatin for, 444
 low density, metabolism of, 864
 metabolism of, 438-439
 aging and, 1525-1526
 body fat distribution and, 126
 plasma, 859-860
 classification of, 861
 metabolism of, 860-865
 production of, 860-863
 properties of, 861
 very low density, production of, 864
 Lipoprotein lipase, deficiency of, familial, 866-869
 elevation of, in obesity, 85
 in regional fat deposition, 88
 Lisinopril, adverse effects of, 331
 clinical efficacy of, 326
 for chronic congestive heart failure, hemodynamic effects of, 321
 renal effects of, 324
 Lithium, teratogenic effects of, 576-577
 Lithotripsy, extracorporeal shock wave, 765-766
 laser, 906
 Liver. See also under *Hepatic; Hepato-*
 abscess of, 847-858
 amebic, 851, 853-856
 pyogenic, 847-853
 alcoholic fibrosis of, 820
 cancer of, liver transplantation for, 1017-1018
 carcinoma of, 985-997. See also *Hepatocellular carcinoma*.
 computed tomography of, 896
 disease of. See *Liver disease*.
 dysfunction of, in hemochromatosis, 836
 failure of, 955-970. See also *Hepatic failure*.
 fibrosis of, drug-induced, 782
 in hemochromatosis, 833
 focal lesions of, imaging of, 897-899
 function of, in pregnancy, 1041
 granulomas of, drug-induced, 783
 imaging of, 895-909

injury to, drug-induced, 782-783, 784
 pathology of, in biliary cirrhosis, 914
 transplantation of, 1011-1039. See also
Liver transplantation.

Liver disease, alcoholic, 815-830
 and hemochromatosis, 833
 and hepatocellular carcinoma, 1001
 biochemical abnormalities in, 821-824
 clinical features of, 821-824
 diagnosis of, 823-824
 histopathology of, 817-821
 liver enzyme abnormalities in, 822
 liver transplantation for, 1016
 pathogenesis of, 815-817
 population at risk for, 821
 prognosis in, 822-823
 therapy for, 824-825
 differential diagnosis of, 899
 drug-induced, 775-792
 acute, 776-777
 chronic, 777-783
 idiosyncratic, 784-785
 mechanisms of, 783-786
 spectrum of, 775-783
 types of, drug categories in, 778-779
 in pregnancy, 1041-1046
 necroinflammatory, chronic, 777
 primary, and hepatocellular carcinoma, 1001-1002

Liver failure, fulminant, 955-970. See also under *Hepatic failure*.

Liver graft, dysfunction of, 1027-1029
 rejection of, 1029-1031

Liver transplantation, 1011-1039
 contraindications to, 1012
 disease recurrence in, 1033
 donor selection for, 1020-1021
 for hepatic encephalopathy, 807
 for primary biliary cirrhosis, 922
 immunosuppressive therapy in, 1023-1027
 indications for, 1012-1020
 medical complications following, 1027-1033
 operative considerations in, 1021-1023
 orthotopic, for fulminant hepatic failure, 965
 patient selection for, 1011-1012
 pediatric, 1020
 pregnancy following, 681
 timing of surgery for, 1011-1012

Livido reticularis, in systemic lupus erythematosus, 1101-1102

J focus of control, in obesity, 52

Loop diuretics, 273-274
 for volume overload, 277

Lovastatin, adverse effects of, 445-446
 and liver disease, 788
 chemistry of, 440
 clinical experience with, 441-444

clinical use of, 445-446
 combination therapy with, 443-444
 for hypercholesterolemia, 437-448, 881
 for hyperlipidemia, 1529
 pharmacokinetics of, 440-441
 pharmacology of, 440
 structural formula of, 440

Low air-loss beds, for pressure ulcer treatment, 1518-1519

Low calorie diets, for obesity, 203-215

Low carbohydrate diets, for obesity, 205, 207

Lower extremities, disability of, role in falls, 1330

Lubricants, for constipation treatment, 1504-1505

Lumbar puncture, in stroke evaluation, 1356

Lumbar spine, stenosis of, in elderly, 1374-1375

Lung. See under *Pulmonary; Respiratory*.

Lupus anticoagulant, patients with, features of, 610
 screening for, 615
 suppression of, and improved pregnancy outcome, 611

Lupus band test, 1065-1066
 for cutaneous lupus erythematosus, chronic, 1264-1266
 subacute, 1269
 for rheumatoid arthritis, 1271
 for scleroderma, 1270-1271
 for systemic lupus erythematosus, 1267-1270
 for vasculitis, 1271

Lupus dermatitis, photosensitive, in acute cutaneous lupus erythematosus, 1095-1096

Lupus erythematosus, bullous, 1098
 in acute cutaneous lupus erythematosus, 1096-1097
 cutaneous, acute, lesions specific for, 1094-1097
 chronic, 1055-1071
 hypertrophic, 1058-1059, 1061, 1064
 immunofluorescence in, 1065-1066
 lupus band test for, 1264-1266
 mucosal, 1060
 pathogenesis of, 1066-1067
 pathology of, 1062-1065
 treatment of, 1068
 subacute, 1073-1090
 annular, 1076
 cutaneous features of, 1074-1078
 definition of, 1074
 disease associated with, 1087
 drug-induced, 1087
 epidemiology of, 1074
 histopathology of, 1078-1079
 immunogenetic associations with, 1083-1085

Lupus erythematosus (*Continued*)
 cutaneous, subacute, immunopathology of, 1078-1079
 laboratory features of, 1081-1083
 lesions specific for, 1097-1099
 lupus band test for, 1269
 manifestations of, 1073-1086
 overlap with other rheumatic disorders, 1086
 systemic features of, 1079-1081
 treatment of, 1085-1086
 cutaneous immunofluorescence for, 1263
 definition of, 1055
 discoid, 1056-1058
 basement membrane zone band in, 1265-1266
 lesions specific for, 1057, 1099
 drug-induced, lupus band test for, 1270
 in elderly, 1377
 juvenile dermatomyositis vs, 1203
 neonatal, lupus band test for, 1270
 penicillamine-induced, 1289
 systemic, activity of, pregnancy and, 606-608
 alopecia in, 1104
 and stroke, 1355
 basement membrane zone band in, 1268
 bullous, lupus band test for, 1267-1268
 chilblain lupus in, 1103-1104
 cutaneous lesions in, 1091-1111
 digital gangrene in, 1104
 diseases associated with, 1107-1108
 fertility in, 605-606
 history of, 1091-1092
 lesions specific for, 1094-1099
 livido reticularis in, 1101-1102
 lupus band test for, 1267-1269
 maternal, management recommendations for, 614-616
 outcome of pregnancy in, 608-609
 pre-eclampsia vs, 616
 reproductive performance in, 609
 mucous membrane lesions in, 1106
 nail changes in, 1107
 nodular lesions in, 1104-1106
 nonspecific cutaneous lesions in, 1100-1107
 periorificial erythema in, 1103
 photosensitivity and, 1093-1094
 Raynaud's phenomenon in, 1103
 soft tissue calcification in, 1106
 telangiectasias in, 1103
 therapy for, cutaneous lesions secondary to, 1108
 vascular lesions in, 1100-1101
 vesiculobullous, 1096-1097
 with leukocytoclastic vasculitis, 1228
 with Sweet's syndrome, 1238

Lupus erythematosus panniculitis, 1113-1126. See also *Panniculitis*.
 Lupus mastitis, in lupus erythematosus panniculitis, 1116
 Lupus nephritis, and maternal death, 607
 Lupus nephropathy, and fetal outcome, 609
 Lupus profundus. See *Panniculitis*.
 Lupus syndrome, neonatal, 613-614
 Lymphocyte count, measurement of, in elderly, 1540-1541
 Lymphoid inflammation, in lupus erythematosus panniculitis, 1117-1119

Macrosomia, in infants of diabetic mothers, 686
 Magnesium hydroxide, cathartic dosage of, 1504
 Malabsorption, in weight control, 254
 Malaise, in pyogenic liver abscess, 849
 Malar rash, in acute cutaneous lupus erythematosus, 1094-1095
 Male, hormonal changes in, with advancing age, 1484-1485
 Malignancy, dermatomyositis and, 1211-1220
 with Sweet's syndrome, 1238
 Malnutrition, protein-calorie, in elderly, 1542-1547
 Malpractice actions, *prima facie* case in, 557-562
 Mammogenesis, in lactation, 584
 Management plan, in medical record, 563
 Mastitis, breastfeeding in, 592
 differential diagnosis of, 596
 Maternal drug therapy, fetal effects of, 591, 611-613
 Maternal-fetal genotype, interaction with environmental teratogen, 568
 Maternal morbidity, causes of, 519-527
 effect on fetus, 546
 in organ transplant recipients, 667-675
 in pre-eclampsia, 624
 Maternal mortality, causes of, 519-527
 definition of, 519
 in organ transplant recipients, 667-668
 with AIDS, 706
 with cardiac disease in pregnancy, 641
 with disseminated intravascular coagulation, 730
 with systemic lupus erythematosus, 607
 Mattress type, in pressure ulcer prevention, 1516
 Meal, thermic response to, 100
 Mean arterial pressure, with angiotensin-converting enzyme inhibitors, 321
 Meclofenemate sodium, cutaneous reactions to, 1281-1282
 Medical care, standard of, breach of, in medical liability, 559-561

Medical consultant, in pregnancy, legal liability of, 557-565
 role of, 541-555, 564-565
recommendations of, compliance with, 542
risk management by, 562-564
Medical disease, breastfeeding and, 583-603
 effect of pregnancy on, 545-547
Medical record, in malpractice litigation, 563
Medication, in pregnancy, risks of, 548-549
Medication compliance, in elderly, 1551-1563
 determinants of, 1554-1556
 promotion of, 1558-1561
Medication regimen, compliance with, promotion of, 1558-1560
 noncompliance with, detection of, 1556-1558
 prevalence of, 1551-1554
Mediterranean fever, familial, 1243
Melanoma cell cultures, extraction of tissue-type plaminogen activator from, 389
Memory, testing of, in acquired cognitive disorder, 1390
Mental status examination, in acquired cognitive disorder, 1389
Meritene, for hyperalimentation, 1546
Mesenteric ischemia, in elderly, emergency operation for, 1418
Metabolic acidosis, 279
Metabolic alkalosis, diuretics for, 279
Metabolic diseases, and hepatocellular carcinoma, 1002-1003
 liver transplantation for, 1016-1017
Metabolic mass, and energy expenditure, 16
Metabolic profile, relationship to body fat distribution, 121-126
Metabolic rate, resting, determinants of, 227
 genetic effect on, 75
 in energy expenditure, 97
 in obesity, 105, 219
 postexercise, 223
Methimazole, teratogenic effects of, 574
Methotrexate, cutaneous reactions to, 1291
 for primary biliary cirrhosis, 922
 teratogenic effects of, 574
Methyl cellulose, cathartic dosage of, 1504
Methyl tert-butyl ether, for gallstones, 766-767
Methyldopa, effect on serum lipids, 465
 for hypertension, in elderly, 1477
 in pregnancy, 672-674
for Raynaud's phenomenon, 1136-1137
in breast milk, 600
Methylmercury, teratogenic effects of, 577
Metoprolol, clinical trials of, 380, 416-418
 clinical use of, 419
 effect on serum lipids, 456
for heart failure, 378
in breast milk, 600
 nifedipine vs, for unstable angina, 426
Metronidazole, for hepatic encephalopathy, 806
in breast milk, 591
Mezlocillin, for urinary tract infections, 1445
Micronutrient requirements, in elderly, 1532-1533
Mid-arm circumference, measurement of, in elderly, 1538-1539
Milk, biosynthesis of, 586
Milk-ejection reflex, 587
 inhibition of, alcohol and, 571
Milrinone, chemical structure of, 304
 for congestive heart failure, 304
 hemodynamic effects of, 306
 pharmacokinetics of, 298
Mineral oil, cathartic dosage of, 1504
Mineral status, effect of aging on, 1540
Mini-Mental Status Examination, of acquired cognitive disorder, 1389
Mitral annulus, calcification of, and stroke, 1355
Mitral insufficiency, in pregnancy, 643
Mitral stenosis, in pregnancy, 642-643
Mixed connective tissue disease, as variant of systemic scleroderma, 1178-1179
 lupus band test for, 1270
Mobility, restricted, and urinary incontinence, 1427
 role in falls, 1329, 1332
Moisture, and pressure ulcers, 1514
Monoclonal antithymocyte globulin, for immunosuppression, in liver transplantation, 1026-1027
Monoclonal gammopathy, with pyoderma gangrenosum, 1255
Mood disorders, clinical description of, 1400
Morbid obesity, definition of, 251
Morphea, in localized scleroderma, 1143-1145
Motor units, synchronization of, and tremor, 1307
Movement tremor, in elderly, 1308
Mucinosis, dermal, in systemic lupus erythematosus, 1106
Mucocutaneous toxicity, penicillamine-induced, 1288
 to gold therapy, 1286
Mucous membrane lesions, in systemic lupus erythematosus, 1106
Multi-infarct dementia, clinical description of, 1396-1398
Multiple gestations, single intrauterine fetal demise in, coagulopathy in, 733-734
Multiple sclerosis, and urinary incontinence, 1424
 tremor with, 1316

Muscle contraction, initiation of, 288

Muscle disease, in dermatomyositis, 1182-1185

- in juvenile dermatomyositis, 1199-1200

Muscle enzymes, in dermatomyositis, 1184

- in juvenile dermatomyositis, 1202

Musculoskeletal system, inflammation in, in subacute cutaneous lupus erythematosus, 1079

Myalgias, in systemic scleroderma, 1172

Myeloma, with pyoderma gangrenosum, 1255

Myocardial contractility, decreased, in pre-eclampsia, 626

effect of calcium antagonists on, 341

Myocardial failure, acute, neurohumoral responses in, 316

Myocardial function, deterioration in, with nifedipine, 346

Myocardial infarction, acute, and stroke, 1354

- calcium channel blockade for, 422-429
- diltiazem for, 427-429
- effect of cocaine on, 479-482
- nifedipine for, 423-426
- recombinant tissue-type plasminogen activator therapy for, 399
- thrombolytic therapy in, 387-407
- verapamil for, 423

beta-adrenergic blockade in, 409-436

calcium channel blockade in, 409-436

cardiovascular mortality risk following, long-term reduction of, 411

cocaine-induced, case summaries of, 480-483

early phase of, beta-adrenoceptor blockade in, 416

prevention of, beta-adrenergic blockade for, 410-411

with coronary artery disease, and congestive heart failure, 293

Myonecrosis, postpartum, 718

Myosin, ATP-bound, in muscle contraction, 289

- in cardiac muscle tension, 286

Myositis, in eosinophilic fasciitis, 1159

Nadolol, in breast milk, 600

Nailfold changes, in dermatomyositis, 1182, 1184, 1212

- in juvenile dermatomyositis, 1195-1196
- in systemic lupus erythematosus, 1106-1107

Naloxone, for weight control, 243-244

Naproxen, cutaneous reactions to, 1280-1281

National Health and Nutrition Examination Survey, 4, 9

Nausea, in pyogenic liver abscess, 849

Necrotizing fasciitis, postpartum, 718

Neglect, with cerebral infarction, 1362

Negligence, malpractice actions for, *prima facie* case in, 557-562

Neomycin, for hepatic encephalopathy, 806

lovastatin with, 443-444

Neonatal lupus syndrome, 613-614

Neonatal morbidity, incidence by gestational age, 522

- predictors of, 523

Neonatal mortality, definition of, 518

- incidence by gestational age, 522
- predictors of, 523

Nephritis, lupus, and maternal deaths, 607

Nephron physiology, diuretic pharmacology and, 272

Nephropathy, diabetic, definition of, 688

- lupus, and fetal outcome, 609

Nephrotic syndrome, lovastatin for, 444

Neural tube defects, with maternal diabetes, 691

Neuroectodermal tumors, childhood, maternal phenytoin therapy and, 572

Neurogenic bladder dysfunction, long-term catheterization for, 1441-1442

Neurologic claudication, in lumbar spinal stenosis, 1374

Neurologic disorders, in Behcet's disease, 1241

Neurologic examination, in acquired cognitive disorder, 1389

Neurologic function, role in falling, 1326, 1332

Neuropsychiatric complications, following liver transplantation, 1032-1033

Neuropsychotropics, and liver disease, 778

Neurotoxins, synergistic action of, in hepatic encephalopathy, 801

Neurotransmitters, and nutrient balance control, 37

- false, in hepatic encephalopathy, 801-802

Neutropenia, with captopril, 331

Newborns, antibiotics contraindicated in, 592

Nibbling, gorging vs, in lipogenesis, 105

Nicardipine, for heart failure, 351-352

Nicotinic acid, for hypercholesterolemia, 881

Nifedipine, clinical experience with, 343-347

- digoxin with, 348-349
- effect on heart rate, 342-343
- for acute myocardial infarction, clinical studies of, 423-426
- results with, 430
- for heart failure, comparison with other agents, 347
- for hypertension in pregnancy, 672-674

Nimiety, in weight control, 252

Nipples, infection of, in lactating diabetic, 597

Nisoldipine, for heart failure, 352

Nitrates, action of, mechanism of, 362-363
in congestive heart failure, 361-371
effects on mortality, 367-368
tolerance to, 365-367

Nitrendipine, for heart failure, 352

Nitrogen balance, negative, in very low caloric diets, 212

Nitroglycerin, for acute hypertension in pregnancy, 632-633
nifedipine vs, 347
therapy with, tolerance to, 366

Nitroprusside, for acute hypertension in pregnancy, 631-632
nifedipine vs, 348

Nodular lesions, in lupus erythematosus panniculitis, 1114
in systemic lupus erythematosus, 1104-1106

Nonsteroidal anti-inflammatory agents, chemical classification of, 1276
cutaneous reactions to, 1275-1283
fetal effects of, 612

Norepinephrine, for congestive heart failure, 301

Norton scale, of pressure ulcer risk, 1515

Nortriptyline, cathartic dosage of, 1504

Nutrients, balance of, afferent signals of, 34-36
and obesity, 29-45
control of, 30-34, 36-38
restriction of, in weight-loss diet, 207
utilization of, 32

Nutrition, and aging, 1531-1549
and pressure ulcers, 1516, 1519
assessment of, in elderly, 1536-1542
deficiencies of, after gastric restriction surgery, 260
in hepatic encephalopathy, 806-807
in weight control program, 192
planning of, for wellness, 1532-1535

Nutritional supplementation, for alcoholic liver disease, 825

Obese personality, 49-52

Obesity, 1-269
age at onset, 162-165
and exercise, 217-236
behavioral management of, 185-201
clinical evaluation of, 174-181
algorithm for, 178-181
concept of cure in, 237
definition of, 7-8, 161
development of, factors in, 173-174, 177
diagnosis and prevalence of, 1-13
diet and, 20-22, 171-172, 203-215
drug-induced, 172-173
drug treatment of, 237-249
eating style in, 54-56

economic factors in, 173-174
endocrine aspects of, 139-160, 170
energy dynamics in, 97-110, 170-171, 219-227
etiological factors in, 165-174, 176-177
genetics in, 57, 67-81, 165-169
health risks of, 111-138
inconsistent findings in, 115-118
heterogeneous phenotype of, 67-68, 118-120

hypothalamic, 22-23, 172

in animals, 23

in familial hypertriglyceridemia, 872

morbid, 251

multifactorial phenotype of, 68-69

nutrition in, 29-45, 100-103

prevalence of, 8-10

psychological factors in, 47-66, 173-174

relation to health, 111-115

risks of, 118, 178-181

social factors in, 173-174

surgical treatment of, 251-264
anatomic-physiologic principles in, 252-254
candidates for, 251
complications of, 259-261
methods of, 252-256
results of, 256-261
techniques in, 254-256
syndromes of, comparison of, 167
thinking style in, 52
types of, 68

Ocular disorders, in Behcet's disease, 1241

Old age, pharmacodynamic changes in, 489
pharmacokinetic changes in, 488-489

Oliguria, following liver transplantation, 1033

Opioid antagonists, for chronic constipation, 1506
for weight control, 243-244

Optifast diet, for obesity, 209

Oral supplements, for hyperalimentation, 1546

Organ transplant recipients, pregnancy in, 667-683

Organic mental syndromes, clinical descriptions of, 1394-1400

Orthostatic hypotension, 1337-1349. See also under *Hypotension*.

Osmolite HN, for hyperalimentation, 1545

Osmotic agents, for constipation, 1504-1506

Osteoarthritis, in elderly, 1372-1373
complications of, 1373-1375

Osteochondrosis, intervertebral, in elderly, 1373-1374

Osteomalacia, with osteoporosis, 1464

Osteomyelitis, and pressure ulcers, 1520

Osteoporosis, in elderly, 1455-1470
diagnosis of, 1457-1459
in men, 1459

Osteoporosis (*Continued*)
 in elderly, medical conditions associated with, 1459
 risk factors for, 1456-1457
 treatment of, 1460-1467
 in primary biliary cirrhosis, 912

Ovarian function, in obesity, 145-146, 170

Ovarian veins, acute postpartum thrombosis of, 717

Overeating, and obesity, 171
 chronic, adaptation to, 76-78
 definition of, 47
 response to, 100-103

Overflow incontinence, 1429-1430. See also *Urinary incontinence*.

Overlap syndrome, in dermatomyositis, 1185-1186

Overweight, measurement of, 174-175

Oxandrolone, for alcoholic liver disease, 824

Oxicans, cutaneous reactions to, 1282-1283

Oxygen, for acute asthma in pregnancy, 657
 hyperbaric, for pyoderma gangrenosum, 1257

Oxygen supply, and cardiac contraction, 291

Oxyphenbutazone, cutaneous reactions to, 1282

Oxyprenolol, for hypertension in pregnancy, 672-674

Oxytocin, effect on milk ejection, 586-587

Pain perception, in elderly, decrease in, 1414

Pallor, in Raynaud's phenomenon, 1133

Pancreas, cancer of, biliary stent for, 904
 endocrine, in obesity, 139-141
 hyposecretion of, with primary biliary cirrhosis, 913

Pancreatitis, in elderly, acute abdomen with, 1416-1417
 in familial hyperlipoproteinemia, 873
 in fulminant hepatic failure, 962

Panniculitis, lupus erythematosus, 1059-1062, 1113-1126
 clinical findings in, 1113-1117
 differential diagnosis of, 1121-1122
 diseases associated with, 1117
 electron microscopic findings in, 1123
 histopathologic findings in, 1117-1121
 immunopathologic findings in, 1122-1123
 in systemic lupus erythematosus, 1105
 incidence of, 1114
 laboratory findings in, 1123-1124
 pathology of, 1064-1065
 relationship to other connective tissue disease, 1121-1122
 treatment of, 1124-1125

Papaverine injection, for erectile dysfunction, 1490

Palpousquamous lesions, in subacute cutaneous lupus erythematosus, 1074

Paramethadion, teratogenic effects of, 573

Parathyroid function, in obesity, 148

Parathyroid hormone, for osteoporosis, 1467

Parenteral hyperalimentation, for protein-calorie malnutrition, 1544

Parkinson's disease, and urinary incontinence, 1424
 dementia in, 1398
 tremor in, 1313-1315

Patent ductus arteriosus, in pregnancy, 644

Pathergy, in pyoderma gangrenosum, 1247

Pathologic tremor, in elderly, 1310-1315

Patient education, medication compliance promotion by, 1555, 1558-1559

Peak expiratory flow rate, in acute asthma, 655

Peliosis hepatis, drug-induced, 782-783

Pelvic infection, persistent, postpartum, 715-716

Pelvic thrombophlebitis, infection and, postpartum, 716-718

Pemphigus, penicillamine-induced, 1289

D-Penicillamine, cutaneous reactions to, 1288-1290

Penis, lacerations of, with urinary tract catheterization, 1447
 prosthesis for, for erectile dysfunction, 1490

Peptic ulcer, in elderly, acute abdomen with, 1416-1417

Percutaneous transluminal coronary angioplasty, following thrombolysis, 401-402

Perinatal morbidity, gestational age at, 520

Perinatal mortality, causes of, 520-521, 523
 definition of, 518
 gestational age at, 520, 523
 in disseminated intravascular coagulation, 730

Peritoneal dialysis, history of, risk of ectopic pregnancy with, 675

Perirethral infections, with urinary tract catheterization, 1446

Personality disturbance, and obesity, 49

Pharmacogeriatric studies, complicating factors in, 491-492

Pharmacotherapy, with behavioral program for obesity, 197

Phenethylamine, for appetite suppression, 239

Phenobarbital, in breast milk, 599

Phenobarbitone, for essential tremor, 1312

Phenothiazine use, role in falls, 1330

Phenylbutazone, cutaneous reactions to, 1282

Phenylpropanolamine, for weight control, 242-243

Phenytoin, for weight control, 243
in pregnancy, 664
metabolism of, and liver disease, 785
teratogenic effects of, 572

Phlebotomy, for hemochromatosis, 839

Phosphodiesterase inhibitors, for congestive heart failure, 303-307

Phospholipid(s), in bile, synthesis of, 756

Phospholipidosis, chronic, drug-induced, 777

Photosensitivity, in subacute cutaneous lupus erythematosus, 1078, 1097
in systemic lupus erythematosus, 1092-1094

Physical activity, energy expenditure from, 106, 227-228
for weight loss maintenance, 198
low level of, and obesity, 170-171

Physical therapy, fall prevention by, 1333-1334
for juvenile dermatomyositis, 1205

Physician-patient relationship, and medical compliance, 1555

Physiologic tremor, in elderly, 1309-1310

Physiology, altered, in pregnancy, 542-544

Pigment stones, in gallbladder, formation of, 758

Pigmentation, abnormalities of, in systemic scleroderma, 1170
with antimalarials, 1285
in hemochromatosis, 836

Pindolol, for heart failure, 378
evidence against, 380

Piperacillin, for urinary tract infections, 1445

Piroxicam, cutaneous reactions to, 1282-1283

Pituitary disorders, in obesity, 141-148, 170

Pityriasisiform lesions, in subacute cutaneous lupus erythematosus, 1075
with gold therapy, 1287

Placebo drug trials, ethical considerations in, 505-506
problems with, 500

Placenta, drug transport across, 569

Placental abruption, and disseminated intravascular coagulation, 730-732

Placental hormones, in fetal diagnosis, 535-536

Plasma lipids, drug effect on, calculations of, 467
transport of, and coronary heart disease risk, 877-879

Plasma volume, in pregnancy, 639
effect on seizure disorders, 661

Plasmin, function of, in coagulation, 726

Pneumonia, aspiration, with dermatomyositis, 1188

Poikiloderma, in dermatomyositis, 1182, 1184, 1212

Polyarteritis nodosa, 1224, 1230

Polyarthritis, symmetrical, inflammatory, in elderly, 1376-1377

Polycythemia, in infants of diabetic mothers, 687

Polymorphonuclear infiltrates, in cutaneous vasculitis, 1226-1227

Polymorphous light eruption, lupus dermatitis vs., 1095

Polymyalgia rheumatica, inflammatory symmetrical polyarthritis vs., 1376-1377

Polyomyositis, with dermatomyositis, 1185

Porphyria, and secondary hemochromatosis, 839
basement membrane zone band in, 1265
with systemic lupus erythematosus, 1108

Portal blood flow, measurement of, 935-937, 940-941

Portal hypertension, 931-953. See also under *Hypertension*.

Portal-systemic collateral circulation, 932
in hepatic encephalopathy, 796-797

Postural hypotension. See *Hypotension, orthostatic*.

Postural sway, in elderly, effect on falling, 1324

Postural tremor, in elderly, 1308
in Parkinson's disease, 1313

Potassium, depletion of, diuretics and, 276

Prader-Willi syndrome, and obesity, 168

Prazosin, effect on serum lipids, 463

Preadipocytes, regulation of, 91

Prednisolone, for chronic hepatitis B, 973

Prednisone, fetal exposure to, 677
for alcoholic liver disease, 824
for asthma in pregnancy, 658
for eosinophilic fasciitis, 1163
for juvenile dermatomyositis, 1204-1205

Pre-eclampsia, and disseminated intravascular coagulation, 736
and liver dysfunction, 1044
chronic hypertension vs., 624
definition of, 623
differential diagnosis of, 671
hemodynamic monitoring in, 625, 627
in renal transplant patients, 672-674
maternal morbidity in, 624
systemic lupus erythematosus vs., 616
therapy for, 627

Pregnancy, acute coagulopathy in, 723-743
and disseminated intravascular coagulation, 727-737
and kidney transplant rejection, 669
anticonvulsant medication in, 662-663
as dynamic state, 549-551
asthma in, 653-660
autoimmune disease in, 605-621
cardiac disease in, 639-651
cardiovascular alterations of, 639-640
dermatomyositis in, 1190-1191

Pregnancy (Continued)

- diabetes in, 685-700
 - management of, first trimester, 689-691
 - second trimester, 691-692
 - third trimester, 692-695
- diagnostic procedures in, 544-545
 - interpretation of, 547-548
- factors unique to, 542-551
- human immunodeficiency virus infection in, 701-711
- hypertensive crisis in, 623-638
- in renal transplant recipients, 667-683
- infections in, 713-721
- insulin action in, 686
- liver disease in, 1041-1046
 - cirrhosis, 1044-1045
 - fatty liver, 1043-1044
 - intrahepatic cholestasis, 1043
 - pre-eclampsia/eclampsia, 1044
 - viral hepatitis, 1041-1043
- lupus activity in, 606-610
- medical disease in, 545-547
- medical problems in, 517-752
- medications in, risks of, 548-549
- physiology in, 550, 685-686
 - alterations in, 542-544
- respiratory changes in, 653-654
- role of medical consultant in, 541-555
- seizure disorders in, 661-665
- serum alkaline phosphatase activity during, 545
- surgery in, risks of, 549
- termination of, 517
- tests for, reliability of, 523

Prekallikrein, levels in pregnancy, 727

Premature labor, risk of, in renal transplant patients, 680

- tocolytic therapy for, 524

Prematurity, morbidity with, 521-522

- risk factors for, 528-529
 - with maternal renal transplant, 676

Prenatal injury, evidence for, 526

Prescription medications, noncompliance with, detection of, 1557

- prevalence of, 1551-1554

Pressure ulcers, in elderly, 1511-1524

- assessment of, 1516-1517
- classification of, 1511
- complications of, 1514-1515
- infection with, 1514
- local care of, 1520-1522
- pathogenesis of, 1513-1514
- pathophysiology of, 1512-1514
- prevalence of, 1512
- prevention of, 1515-1516
- risk factors for, 1512-1514
- treatment of, 1516-1522

Presyncope, in stroke, 1353

Primidone, for essential tremor, 1312

- in breast milk, 599

Problem-oriented medical record, in medical consultation, 563

Probucol, for hypercholesterolemia, 881

Progesterone, in pregnancy, effect on seizure disorders, 661

Progressive systemic sclerosis, with dermatomyositis, 1185

Prolactin, in obesity, 143

- role in milk production, 585-587

Propionic acids, cutaneous reactions to, 1280-1281

Propranolol, clearance rate of, 490, 492

- clinical use of, 419
- effect on serum lipids, 455
 - for esophageal varices, 946
- for essential tremor, 1312
- for heart failure, 378
 - evidence against, 380
- in breast milk, 600
- in elderly, 489-491
- intravenous, clearance of, age and, 492
- kinetics of, age and sex in, 491
- systemic availability of, 490

Propylthiouracil, for alcoholic liver disease, 824

- teratogenic effects of, 574

Prostacyclins, for hepatic encephalopathy, 807

Prostate cancer, in obesity, 115

Prosthetic heart valve, and stroke, 1354

Protein, requirements for, in elderly, 1532-1533, 1535, 1541-1542

Protein C, function of, in coagulation, 726

Protein-calorie malnutrition, in elderly, 1542-1547

Proteinuria, in cutaneous vasculitis, 1225

- in renal transplant patients, in pregnancy, 674
 - with captopril, 331

Prothrombin ratio, in liver failure, 943

Proximal tubule, diuretic action in, 271-273

Pruritus, in primary biliary cirrhosis, 911

Pseudoporphyrin, naproxen-induced, 481

Psoriasis, with corticosteroid withdrawal, 1284

- with systemic lupus erythematosus, 1075, 1108
- worsening of, with antimalarials, 1285

Psychiatric complications, following liver transplantation, 1032-1033

Psychiatric intervention, for chronic constipation, 1507

Psychological factors, in medical compliance, 1553, 1559

- in obesity, 47-66

Psychosocial examination, in acquired cognitive disorder, 1388, 1391

Psyllium, cathartic dosage of, 1504

Puerperal infection, pathophysiology of, 713-716

Puerperium, anticonvulsant medication in, 662-663

Pulmocare, for hyperalimentation, 1545

Pulmonary circulation, in pregnancy, 640

Pulmonary disease, with dermatomyositis, 1186-1188
with systemic scleroderma, 1172

Pulmonary edema, in pre-eclampsia, 627
nifedipine for, 344

Pulmonary emboli, with postpartum pelvic thrombophlebitis, 717

Pulmonary hypertension, in pregnancy, 645-646

Pulmonary maturity, fetal, in maternal diabetes, 693-694

Pulmonary vasculature, effect of nitrates on, 363

Pulse therapy, for pyoderma gangrenosum, 1257-1258

Pulsus paradoxus, in acute asthma, 654, 655

Purpura, in cutaneous vasculitis, 1224-1225

Pyelonephritis, with urinary tract catheterization, 1447-1448

Pyoderma gangrenosum, 1243-1244, 1247-1261
atypical, 1250
clinical features of, 1248-1250
conditions associated with, 1252-1255
definition of, 1247
differential diagnosis of, 1255-1256
etiology of, 1251-1252
evaluation of, 1255-1256
histopathology of, 1250
pathogenesis of, 1251-1252
treatment of, 1256-1258

Pyostomatitis vegetans, in pyoderma gangrenosum, 1249-1250

Pyrazolones, cutaneous reactions to, 1281

Quality of life, in obesity, effect of surgery on, 258-259

Quinacrine, cutaneous reactions to, 1284-1285

Quinidine, and digitalis toxicity, 299

Radiation, fetal effects of, 534, 547

Rash, in juvenile dermatomyositis, 1195

Raynaud's disease, 1127-1128

Raynaud's phenomenon, and disease, 1127-1141
clinical evaluation of, 1133-1134
conditions associated with, 1130-1133
definition of, 1127-1128
epidemiology of, 1129-1130
in systemic lupus erythematosus, 1102
in systemic scleroderma, 1167, 1170, 1174

laboratory evaluation of, 1134
pathophysiology of, 1128-1129
prevention of, 1135-1136
sympatholytics for, 1136-1137
therapy for, 1134-1139

Rebound tenderness, in acute abdomen, 1414

Recanalization, with thrombolytic therapy, 396

Recombinant tissue-type plasminogen activator, administration of, 390-391
clinical development of, 388-389
efficacy of, 391-394
for acute myocardial infarction, 387-407
mortality with, 400, 401
patency rates with, 393
patient selection for, 389-390
pharmacology of, 387-388
safety of, 394-397
side effects of, 396-397

Reinforcement, in weight control program, 193

Relationship techniques, in weight control program, 192

Reliability, of tests, definition of, 537

Renal. See *Kidney*.

Renin-angiotensin-aldosterone system, 317-319

Repositioning, in pressure ulcer prevention, 1515-1516

Reserpine, in breast milk, 600

Respiratory insufficiency, in obesity, effect of surgery on, 258
with dermatomyositis, 1188

Respiratory muscles, accessory, use of, in acute asthma, 655

Respiratory physiology, in pregnancy, changes in, 550, 653-654

Respiratory rate, in acute asthma, 655

Rest tremor, in elderly, 1308
in Parkinson's disease, 1313

Retained dead fetus syndrome, and disseminated intravascular coagulation, 732-733

Reticuloendothelial system, defects in, and hemochromatosis, 835

Retinoids, cutaneous reactions to, 1293-1294

Reye's syndrome, microvesicular steatosis in, 958

Rheumatic syndromes, in elderly, treatment of, 1371-1381

Rheumatoid arthritis, inflammatory symmetrical polyarthritis vs, 1376-1377
juvenile, juvenile dermatomyositis vs, 1203

lupus band test for, 1271
with cutaneous lupus erythematosus, 1086
with dermatomyositis, 1185
with leukocytoclastic vasculitis, 1228
with Sweet's syndrome, 1238

Rheumatoid-like nodules, in systemic lupus erythematosus, 1105
 Rheumatologic disorders, drugs for, cutaneous reactions to, 1275-1298
 Rubavirin, for chronic hepatitis B, 976
 Right-to-left shunts, in pregnancy, 644-648
 Risk management, in medical consultation, 562-564
 Ro-antibody, in subacute cutaneous lupus erythematosus, 1099
 Rubral tremor, 1316

Salicylates, cutaneous reactions to, 1277-1278
 Salsalate, cutaneous reactions to, 1278
 Salt intake, increase in, for orthostatic hypotension, 13
 restriction of, for hypertension, 1474
 Sample population, for drug trials, selection of, 504
 Sarcomere, length of, 284-285
 Satiety, in weight control, 252
 Schistosomiasis, and hepatocellular carcinoma, 1000-1001
 Schizophrenia, medication noncompliance in, 1553
 Scleredema, as variant of systemic scleroderma, 1177-1178
 Scleroderma, and Raynaud's phenomenon, 1130-1132
 linear, 1145
 localized, 1143-1156
 associated findings in, 1147
 clinical features of, 1143-1147
 differential diagnosis of, 1151-1153
 "en coup de sabre" lesion in, 1145-1146
 epidemiology of, 1148-1149
 histology of, 1148
 laboratory abnormalities in, 1149-1150
 onset findings in, 1147
 overlap with systemic disease, 1150-1151
 pathogenesis of, 1148
 prognosis in, 1151
 subcutaneous involvement in, 1147
 treatment of, 1153-1154
 variants of, 1143-1147
 lupus band test for, 1270-1271
 spectrum of, 1168
 systemic, 1167-1180
 antibodies to, 1173
 classification of, 1167-1172
 cutaneous features of, 1167-1172
 laboratory findings in, 1172-1173
 pathogenesis of, 1173-1174
 prognosis in, 1176-1177
 systemic features of, 1171-1172

therapy for, 1174-1176
 variants of, 1177-1179
 Scleromyxedema, as variant of systemic scleroderma, 1177-1178
 Sclerotherapy, for esophageal varices, 945-947
 Screening, for weight control program, 194
 Sedimentation rate, elevated, in cutaneous vasculitis, 1226
 in leukocytoclastic vasculitis, 1231
 in pyogenic liver abscess, 849
 Seizure, stroke vs, 1355
 Seizure disorders, in pregnancy, 661-665
 Self-monitoring, in behavioral programs for obesity, 190
 Senile gait, definition of, 1326
 Senile tremor, in elderly, 1310-1311
 Senna extract, cathartic dosage of, 1504
 Sepsis, and coagulopathy, 734-735
 in elderly, findings in, 1419
 Serotonin neurotransmitters, anorexiant drugs acting on, 241-242
 Serum alkaline phosphatase activity, during pregnancy, 545
 Serum lipids. See *Lipids, serum*.
 Serum sickness, as hypersensitivity vasculitis, 1223, 1229
 Set-point, body weight, energy expenditure and, 19-19
 Sex hormones, in regional fat deposition, 88
 Sexual function, with advancing age, 1483-1495
 Sharp's syndrome, as variant of systemic scleroderma, 1178-1179
 Shearing forces, and pressure ulcers, 1514
 Sheepskin, for pressure ulcer treatment, 1517
 Shoulder, arthritis in, in elderly, 1376
 Shy-Drager syndrome, orthostatic hypotension vs, 1342
 Sickness Impact Profile, in obesity, 259
 Silicone catheters, for urinary tract catheterization, 1442
 Sjögren's syndrome, inflammatory symmetrical polyarthritides vs, 1376-1377
 with cutaneous lupus erythematosus, 1086
 with dermatomyositis, 1185
 with leukocytoclastic vasculitis, 1228
 with Sweet's syndrome, 1238
 with systemic lupus erythematosus, 1107
 Skeletal hyperostosis, diffuse idiopathic, in elderly, 1375
 Skin, breakdown of, with incontinence, long-term catheterization for, 1441-1442
 infections of, with corticosteroid withdrawal, 1284
 protection of, in juvenile dermatomyositis, 1206
 Skinfold measurements, and health risks, 119

for body fat determination, 4-7
 genetic effect on, 72
 in elderly, 1538-1539

Smoking, and impotence, 1487
 cessation of, for hypertension in elderly, 1474
 effect on resting metabolic rate, 106

Social support, in weight control program, 193

Sodium ion exchange, increase in, inotropic action on, 296

Sodium nitroprusside, for acute hypertension in pregnancy, 631-632

Sodium-potassium-chloride step, of loop diuretics, effects of blocking, 273-274

Soft tissue calcification, in systemic lupus erythematosus, 1106

Somatomedin, in obesity, 142

Somatostatin, for esophageal varices, 945

Sorbitol, for chronic constipation, 1504, 1506

Spermatogenesis, decreased, with aging, 1484

Spherocytosis, hereditary, and secondary hemochromatosis, 838

Sphincterotomy, endoscopic, of bile duct, 768, 903

Spina bifida, with maternal diabetes, 691

Spinal cord lesions, and urinary incontinence, 1424

Spine, degenerative changes of, in elderly, complications of, 1373-1375

Spirometry, in acute asthma, 655

Standing, blood pressure response to, 1338-1340

Stature, calculation of, in elderly, 1538

Status epilepticus, in pregnancy, 662

Steatonecrosis, alcoholic, 817-819

Steatorrhea, in primary biliary cirrhosis, 912

Steatosis, alcoholic, 817-818
 drug-induced, 777
 microvesicular, in Reye's syndrome, 958

Sterilization, in AIDS patient, 706

Steroids. See also *Corticosteroids*.
 anabolic, and hepatocellular carcinoma, 1004
 for osteoporosis, 1467
 for maternal systemic lupus erythematosus, 616
 for septic shock, 735

Stillbirth, definition of, 518

Stimulus control, in behavioral programs for obesity, 190

Stool impaction, and urinary incontinence, 1427

Stool softeners, for constipation treatment, 1504-1505

Streptokinase, recombinant tissue-type plasminogen activator vs, 394-395

Streptomycin, teratogenic effects of, 577

Stress, and orthostatic hypotension, 1340

Stress incontinence, 1424, 1429-1430. See also *Urinary incontinence*.
 and sexual problems, in aging females, 1491

Stroke, in elderly, 1351-1369
 diagnosis of, 1356-1358
 differential, 1352-1356
 features of, 1358-1359
 recurrence of, 1363
 treatment of, decisions in, 1358-1360
 programs for, 1360-1366

Suckling, milk stimulation by, 588

Sucrose polyester, for weight control, 247

Sulindac, cutaneous reactions to, 1278-1279

Sulfonamides, for pyoderma gangrenosum, 1257

Sulfones, for pyoderma gangrenosum, 1257

Sunscreen, for cutaneous lupus erythematosus, 1068

Suppositories, for chronic constipation, 1506

Suprapubic catheters, for urinary incontinence, 1451

Suprofen, cutaneous reactions to, 1281

Surgery, for obesity, 251-264
 with behavioral program, 197
 for pressure ulcers, 1521-1522
 in pregnancy, risks of, 549

Sway, in elderly, effect on falling, 1324

Sweet's syndrome, findings in, 1237-1239

Sympathetic nervous system, effect of cocaine on, 476-478
 role in thermic effect of food, 101

Sympatholytic agents, for hypertension, in elderly, 1477
 in pregnancy, 628-630
 for Raynaud's phenomenon, 1136-1137

Sympathomimetic amines, adrenergic receptor activity of, 302

Synchrony, in muscle contraction, 286-287

Syncop, in stroke, 1353

Systemic lupus erythematosus. See under *Lupus erythematosus*.

Systemic sclerosis, localized scleroderma vs, 1151-1152

Systolic dysfunction, in congestive heart failure, 292

T cells, circulating levels of, in primary biliary cirrhosis, 917

Tachycardia, catecholamine-mediated, beta-blocker therapy for, 375-376
 in juvenile dermatomyositis, 1200

Taste disturbance, with captopril, 331

Telangiectasia, in juvenile dermatomyositis, management of, 1206
 in systemic lupus erythematosus, 1103
 in systemic scleroderma, 1167-1169, 1171

Temporal arteritis, and stroke, 1355

Teratogen, definition of, 567

Teratogenesis, mechanisms of, 569

Teratology, principles and practice of, 567-582

Terbutaline, for asthma in pregnancy, 658

Testicular dysfunction, in obesity, 143-145

Testicular size, decreased, with aging, 1484

Testosterone, and sexual function, in aging females, 1492

decrease in, with aging, 1484

for erectile dysfunction, 1489

levels of, in obesity, 143-144

side effects of, 1490

Tetracycline, teratogenic effects of, 577-578

Tetralogy of Fallot, in pregnancy, 644-645

Thalamotomy, for essential tremor, 1311

Thalassemia, and secondary hemochromatosis, 838

Thalidomide, teratogenic effects of, 578

Theophylline, for acute asthma in pregnancy, 656

Thermogenesis, facultative, in energy expenditure, 99

postprandial, 223

Thermogenic drugs, for weight control, 244-245

Thiazides, effect on serum lipids, 452

for idiopathic hypercalcemia, 278

for osteoporosis, 1467

Thinking style, in obesity, 52

Thorotrast, and hepatocellular carcinoma, 1005-1006

Thrombin, increased activity of, in pregnancy, 724

Thrombocytopenia, neonatal, azathioprine and, 677-678

Thromboembolism, in elderly, treatment of, 1360-1365

Thrombolytic therapy, administration protocol for, 390-391

contraindications to, 390

for acute myocardial infarction, 387-407

patient selection for, 389-390

reperfusion with, 397-400

safety of, 394-397

treatment after, 400

Thrombophlebitis, pelvic, postpartum infection and, 716-718

Thyroid disease, breastfeeding in, 597-598

Thyroid function, in obesity, 147-148

Thyroid hormone, for weight control, 244

Thyroxine, role in lactation, 586

Tidal volume, in pregnancy, 654

Time/bowel retraining, in constipation treatment, 1503

Timolol, clinical use of, 419

in breast milk, 601

Tissue-culture solutions, for pressure ulcer treatment, 1521

Tissue iron, quantitation of, 834

Tissue-type plasminogen activator. See *Recombinant tissue-type plasminogen activator*.

Tobec, for body fat determination, 3

Tocolytic agents, for premature labor, 524

Tolmetin, cutaneous reactions to, 1279

Toxemia, seizure disorder vs, 662

Toxic epidermal necrolysis, bullae with, 1279

Toxic megacolon, with chronic constipation, 1507

Toxic shock syndrome, breastfeeding in, 592

Toxin theory, of Alzheimer's disease, 1385-1386

Toxins, and hepatocellular carcinoma, 1003-1006

synergistic action of, in hepatic encephalopathy, 801

Transferrin factor, for chronic hepatitis B, 977

Transferrin, laboratory standards for, 1541

measurement of, in elderly, 1539

receptors of, in hemochromatosis, 835

Transforming growth factor-alpha, in hepatocellular carcinoma, 992-993

Transient ischemic attack, carotid endarterectomy for, 1364

in elderly, diagnostic evaluation of, 1356-1358

signs of, 1353

Trauma, and lupus erythematosus panniculitis, 1116

Trauma theory, of Alzheimer's disease, 1386

Travasorb, for hyperalimentation, 1545

Trazadone, cathartic dosage of, 1504

Tremors, in elderly, 1307-1319

classification of, 1308-1310

definition of, 1307-1308

drug-induced, 1310-1311, 1316

frequency of, 1309

functional, 1317

in Parkinson's disease, 1313-1315

post-traumatic, 1317

Trichinosis, juvenile dermatomyositis vs, 1203

Tricyclic antidepressants, cathartic dosage of, 1504

Triglycerides, increased hepatic synthesis of, thiazide-induced, 450

lovastatin for, 444

regulation of, 84

Trimethadione, in pregnancy, 663

teratogenic effects of, 573

Trimethaphan, for acute hypertension in pregnancy, 630

Trimethoprim-sulfamethoxazole, for urinary tract infections, 1445

Troponin C-Ca²⁺ responsiveness, increase in, inotropic action on, 296-297

Tuberculosis, breast-feeding in, 592

Tubular physiology, review of, 271

Tumor, and urinary incontinence, 1424
stroke vs, 1355

Tyrosinemia, and hepatocellular carcinoma, 1002

Ulcerations, in pyoderma gangrenosum, 1248

Ulcerative colitis, in primary sclerosing cholangitis, 1014
with pyoderma gangrenosum, 1249, 1253
with Sweet's syndrome, 1238

Ultrasoundography, endoscopic, 906
for gallstones, 759-760
in fetal diagnosis, 532-533
in second trimester, in diabetes, 691-692

Ultraviolet light, and chronic cutaneous lupus erythematosus, 1067
and systemic lupus erythematosus, 1093

Undernutrition, response to, 100-103

Underwater weighing, for body fat determination, 2

Urethra, function of, changes with aging, 1426
incompetence of, in urinary incontinence, 1424-1426
injuries to, with urinary tract catheterization, 1447

Urge incontinence, 1428-1430. *See also Urinary incontinence.*

Urinary. *See also Bladder.*

Urinary flow rate, in urinary incontinence, 1425

Urinary incontinence, in dementia, treatment of, 1405
in elderly, 1423-1439
established causes of, 1428-1430
evaluation of, 1430-1435
functional, 1425
indwelling catheters for, 1441
medical causes of, 1426-1428
medications contributing to, 1428
pathophysiology of, 1424-1425
prevalence of, 1423-1424
treatment of, 1433
prevention of, in pressure ulcer prevention, 1516

Urinary stones, with urinary tract catheterization, 1448

Urinary tract catheterization, catheter care in, 1450
catheter choice for, 1442-1443
closed drainage system for, 1443-1444
complications of, local, 1443-1447
systemic, 1447-1449
indications for, 1441-1442
intermittent, for urinary incontinence, 1436, 1450-1451

long-term, alternatives to, 1450-1451
in elderly, 1441-1454

Urodynamics, bedside, interpretation of, 1432, 1434
in urinary incontinence, 1425-1426

Uroscopy, with urinary tract catheterization, 1448

Ursodeoxycholate, for gallstones, 763-764

Ursodeoxycholic acid, for primary biliary cirrhosis, 921-922

Urticaria, in systemic lupus erythematosus, 1101

Uterine infection, risk factors for, 713

Uterine pain, with abruptio placentae, 731

Uteroplacental insufficiency, and perinatal complications, 522

Vacuum tumescent device, for erectile dysfunction, 1489

Vaginal bleeding, with abruptio placentae, 731

Vagotomy, for weight control, 256

Validity, of tests, definition of, 537

Valproate, metabolism of, and liver disease, 785

Valproic acid, in breast milk, 599
in pregnancy, 664
teratogenic effects of, 573

Varicella-zoster infection, breastfeeding in, 594

Vascular disease, and impotence, 1486-1487

Vascular lesions, in systemic lupus erythematosus, 1100-1101

Vascular resistance, systemic, in pregnancy, 639-640

Vasculitis, and stroke, 1355
classification of, 1222
cutaneous, 1221-1235
clinical features of, 1224-1226
definition of, 1221
laboratory findings in, 1226
pathology of, 1226-1228
systemic involvement in, 1225
in elderly, 1377-1378
leukocytoclastic, diseases associated with, 1228-1231
evaluation of, 1231-1233
history in, 1232
laboratory examinations in, 1231
microscopic findings in, 1237
subgroups of, 1228-1231
treatment of, 1232
lupus band test for, 1271
lymphocytic, in lupus erythematosus pan-niculitis, 1119
pathogenesis of, 1222-1224
pustular, 1239

Vasoactive agents, for systemic scleroderma, 1175

Vasoconstriction, catecholamine-induced, beta-blocker therapy for, 375

Vasodilators, effect on serum lipids, 465-466 for acute hypertension in pregnancy, 630-634 for pre-eclampsia, 627 for Raynaud's phenomenon, 1137-1138 nifedipine vs, 347-348

Vasopressin, diuresis with, 280-281 effect on hepatic venous pressure, 941 for esophageal varices, 944 in obesity, 148 levels of, effect on renin-angiotensin-aldosterone system, 319

Vasospasm, in Raynaud's phenomenon, 1129

Vegetarian diets, for obesity, 204

Venesection, therapeutic, for hemochromatosis, 839

Veno-occlusive disease, drug-induced, 782

Veno-venous bypass system, for liver transplantation, 1022

Venous pooling, and orthostatic hypotension, 1341

Ventricular filling pressure, effect of nitrates on, 362-363

Ventricular function, following thrombolytic therapy reperfusion, 397-400

Ventricular preload, effect of calcium antagonists on, 341-342

Ventricular septal defect, in pregnancy, 644

Verapamil, and digitalis toxicity, 299 effect on heart rate, 342 for acute myocardial infarction, clinical studies of, 423 results with, 430 nifedipine vs, 349-350

Vertebral fractures, in elderly, 1375

Vertebral joints, arthritis involving, in elderly, 1373

Very low calorie diets, for obesity, 203-215

Vesicoureteral reflux, with urinary tract catheterization, 1449

Vidarabine, for chronic hepatitis B, 975

Vinyl chloride, and hepatocellular carcinoma, 1005-1006

Viral hepatitis, 971-983. See also *Hepatitis*.

Viral infection, and Behcet's disease, 1240 and dermatomyositis with malignancy, 1216 and juvenile dermatomyositis, 1194 fetal exposure to, 679

Visuospatial tasks, testing of, in acquired cognitive disorder, 1390

Vitamin(s), requirements for, in elderly, 1532-1533

Vitamin D, for osteoporosis, 1464-1465

Vitiligo, in juvenile dermatomyositis, 1196, 1198

Vitiligo-like leukoderma, in subacute cutaneous lupus erythematosus, 1076

Vivonex T.E.N., for hyperalimentation, 1545

Volume overload, diuretics in, 276-277

Vomiting, in pyogenic liver abscess, 849 with gastric restriction surgery, 259

Von Willebrand's disease, coagulopathy in, 737

Waist-to-hip ratio, and health risks, 120 and metabolic profile, 121 for body fat determination, 5

Walking program, effect on body weight, 231

Wandering, in dementia, treatment of, 1404

Warfarin, embryopathy with, 571 for stroke prophylaxis, 1363

Weakness, in juvenile dermatomyositis, 1199

Wegener's granulomatosis, in elderly, 1378 with cutaneous leukocytoclastic vasculitis, 1229

Weight, calculation of, in elderly, 1537-1538 change in, after gastric restriction surgery, 260 whole body metabolic response to, 24 in body fat determination, 3 monitoring of, in protein-calorie malnutrition, 1543

Weight-height index, 4

Weight loss, diets for, 203-215 for hypertension in elderly, 1474 maintenance of, strategies for, 197-199 programs for, 191-192 surgical approach to, 251-264

Weight training, effect on body composition, 233

Wellness, nutritional planning for, 1532-1535

Wheezing, in acute asthma, 655

Wilson's disease, liver transplantation for, 1017

Wound infection, postpartum, life-threatening, 718-719

Wound irrigation, for pressure ulcer treatment, 1521

X-linked obesity, 169

Xanthomas, eruptive, in familial type V hyperlipoproteinemia, 873

Zinc, deficiency in, and impotence, 1488

Zinc sulfate, for pressure ulcer treatment, 1519

